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ABSTRACT
Current limitations regarding the treatment of metastatic epithelial ovarian cancer 
(EOC) are attributed to our poor overall understanding of its progression due to the 
limited number of appropriate model systems. To this end, I have characterized EOC 
tumour growth and angiogenesis using the innovative chick chorioallantoic membrane 
(CAM) model system. Bone morphogenetic protein (BMP) signaling has been implicated 
in multiple processes of EOC metastasis, although its role in tumour angiogenesis has 
never been assessed. I found an inverse correlation between the level of BMP signaling in 
mouse EOC cells and their abilities to induce angiogenesis both in vitro using HUVEC 
tube formation assays and in vivo using a chick CAM angiogenesis collagen onplant 
assay. These results support the further implementation of the chick CAM as an 
important tool to study EOC metastasis. Additionally, the putative anti-angiogenic role of 
BMP4 signaling from my work highlights potential future implications for this pathway 
in prognostics and treatment of EOC.
Keywords: Bone Morphogenetic Protein, Chick Chorioallantoic Membrane, Epithelial 
Ovarian Cancer, Angiogenesis, Tumour Formation, Metastasis
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1.1 Overview of ovarian cancer
1.1.1 Prevalence and mortality
Ovarian cancer is the seventh most common type of cancer in women, and it is 
estimated that there were 2,600 new cases of ovarian cancer in Canada this past year.
This represents 3% of the 83,900 total new cases of cancer among women in Canada in 
2010 (Canada 2010). Although this is a fairly small percentage of the total number of 
new cancer incidences, ovarian cancer is the most lethal gynecologic cancer in the 
western world, and is responsible for more deaths than endometrial and cervical cancer 
combined (Ozols, Bookman et al. 2004). This is highlighted by the fact that it was the 
fifth deadliest cancer in terms of mortality in women, and accounted for approximately 
5% of the 36,200 cancer related deaths among females in Canada in 2010 (Canada 2010). 
Although much research has gone into developing treatments for ovarian cancer, there 
was only a 0.5% decrease in mortality rates among women with ovarian cancer in Canada 
between 1996 and 2005. Conversely, other cancers such as lung and breast cancer have 
mortality rates that have decreased by over 2% during the same period of time.
1.1.2 Detection and screening for ovarian cancer
These recent successes in declining mortality rates for other cancers such as lung 
and breast has been largely attributed to important advancements with respect to early
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detection and treatment (Canada 2010). Unfortunately, ovarian cancer is not usually 
detected during its early stages due to a low specificity of recognizable signs and 
symptoms (Goff, Mandel et al. 2007). The most common symptoms that women report 
before they are diagnosed with ovarian cancer are pelvic and abdominal pain, bloating 
and an increased size of abdomen, increased frequency of urination, and a low desire to 
eat for periods of at least 1 year preceding diagnosis. Therefore, patients and physicians 
will often attribute many of these symptoms to other general gynecological concerns such 
as menstrual problems, aging, or menopause (Argento, Hoffman et al. 2008).
The most common methods that are currently used clinically to detect ovarian 
cancer are transvaginal ultrasounds, and the measurement of blood circulating marker 
CA-125 (Argento, Hoffman et al. 2008), which is an antigen that is expressed by the 
coelomic epithelium (Jacobs and Menon 2004). However, there are several processes 
other than ovarian cancer that can disrupt the coelomic epithelium such as pregnancy, 
appendicitis, ovarian cysts, and endometriosis, thereby complicating the interpretations of 
CA-125 blood test results (Cragun 2011). As well, CA-125 can be elevated in other 
cancers such as pancreatic, uterine, and lung cancer. Overall, CA-125 is expressed in 
approximately 50% of early stage ovarian cancers. However, there is a large frequency of 
false positives and false negatives in CA-125 screening, which suggests that this 
screening method is not specific or sensitive enough to be used as a definitive tool to 
diagnose ovarian cancer. The other common screening method that is used to detect 
ovarian cancer is transvaginal ultrasounds, which attempt to differentiate benign from 
malignant masses (Cragun 2011). Although this screening method is argued to be the 
most effective current method for detecting early stage ovarian cancer, it is only able to
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distinguish between benign and malignant lesions between 68-81% of the time. Pelvic 
exams can also be used in an attempt to distinguish between a normal ovary and one that 
possesses early premalignant lesions, but studies show that these exams are only able to 
distinguish between the two 45% of the time.
With respect to assessing a woman’s risk of developing ovarian cancer, high-risk 
populations with a family history of ovarian cancer may be screened for germline 
mutations such as BRCA1 and BRCA2, as women with these mutations have a 
dramatically increased risk of developing ovarian cancer (Antoniou, Pharoah et al. 2003). 
However, screening for these mutations is only an assessment of risk, and does not 
provide a diagnosis of ovarian cancer.
Due to the limited ability of all of these methods to effectively diagnose ovarian 
cancer at early stages, only 19% of new ovarian cancer cases are diagnosed at early 
stages when tumours are still localized to the ovary, whereas approximately 70% of new 
ovarian cancer cases are diagnosed at advanced stages when the cancer has already 
metastasized outside of the ovaries to distant sites within the peritoneal cavity (Jemal, 
Siegel et al. 2008). Unfortunately, once ovarian cancer has metastasized outside of the 
ovaries, standard therapies are much less effective. This can be seen by the fact that 
although the five-year survival rate for ovarian cancer patients who are diagnosed with 
early localized disease is 92%, it decreases to 30% in patients who are not diagnosed until 
the cancer has metastasized to distant sites outside of the ovaries. High mortality in 
ovarian cancer has also been partly attributed to having one of the highest average ages at 
initial diagnoses, with a median age of 63 years (Ozols, Bookman et al. 2004). As a result 
of the current limitations relating to early ovarian cancer detection and the high mortality
associated with these limitations, it is essential to develop better early detection and 
screening methods, as well as prevention strategies. One way that this may eventually be 
achieved is by gaining a thorough understanding of the molecular mechanisms and 
factors that are essential to the development of ovarian cancer.
1.1.3 Origins of ovarian cancer
Epithelial ovarian cancer (EOC) accounts for approximately 90% of all human 
ovarian malignancies, and is believed to originate from the ovarian surface epithelium 
(OSE) (Auersperg, Wong et al. 2001). However, there is also recent evidence to suggest 
that EOC may have alternative origins in the fallopian tubes, which are in close proximity 
to the ovaries (Medeiros, Muto et al. 2006; Levanon, Crum et al. 2008; Karst and 
Drapkin 2010). Germ cell ovarian cancers account for 5% of human ovarian 
malignancies, and stromal cell origins account for the remaining 5% of ovarian cancers 
(Shield, Ackland et al. 2009). The OSE consists of a single layer of flat-to-cuboidal 
mesothelial cells with few distinguishing features, and is separated from the stroma of the 
ovary by an intermediate basement membrane (Auersperg, Wong et al. 2001). 
Functionally, the OSE is responsible for the transportation of molecules to and from the 
peritoneal cavity, and is also involved in the processes of ovulatory rupture and 
subsequent repair.
Although the etiology of ovarian cancer is not completely understood, there are 
several theories that have attempted to explain why EOC may originate from the OSE, 
which are centered around data indicating that the risk of an individual developing EOC 
positively correlates with their number of lifetime ovulatory events (Ozols, Bookman et
5
al. 2004). The best supported theory over the past several decades relating to this data is 
the incessant ovulation hypothesis (Fathalla 1971). This hypothesis suggests that the 
repetitive rupturing of the OSE that occurs during ovulation results in rapid cell 
proliferation during postovulatory repair. The repetition of this process over time may 
lead to mutations in OSE cells, which could eventually lead to the formation of tumour 
cells. The second common hypothesis is the gonadotropin hypothesis (Ozols, Bookman 
et al. 2004). It suggests that the increases in pituitary gonadotropins at the start of each 
ovulation and that can persist for years after menopause can stimulate OSE cells in 
inclusion cysts within the ovary, which may lead to mutations in OSE cells (Konishi, 
K urodaetal. 1999).
There have also been recent studies suggesting alternative origins of EOC other 
than the OSE. For example, it has been suggested that high grade serous ovarian 
carcinomas may originate from the fallopian tubes. This is based partly on observations 
that ovarian carcinomas have little resemblance to OSE cells, and instead have a closer 
resemblance to the epithelium of the fallopian tube (Levanon, Crum et al. 2008). 
Additionally, studies have examined the ovaries and fallopian tubes of BRCA1+ women 
at high risk for ovarian cancer who had bilateral salpingo-oophorectomies. Upon 
examination, it was found that early stage serous carcinomas were found in several 
patients in sections of the fallopian tubes, whereas none were found in the ovaries 
(Medeiros, Muto et al. 2006). Therefore, it is suggested that since the fallopian tube and 
particularly the fimbria have a close proximity to the ovaries and are exposed to the same 
microenvironment, transformed fallopian tube epithelial cells may shed into the
6
peritoneal cavity or migrate to the ovaries during the early stages of cancer progression 
(Karst and Drapkin 2010).
1.1.4 Subtypes of epithelial ovarian cancer
There are several subtypes of epithelial ovarian cancer that can be distinguished 
upon initial diagnosis based on tumour cell morphology. The four most common 
histological subtypes of ovarian cancer are serous, clear cell, endometrioid, and mucinous 
carcinomas (Cho and Shih Ie 2009). Each of these subtypes is unique in terms of 
incidence, genetic mutations, appearance, and response to treatment. Serous carcinomas 
account for approximately 70% of all EOC cases, clear cell account for 10%, 
endometrioid account for 7%, and mucinous account for 3%. Additionally, serous 
carcinomas are further classified into high-grade serous and low grade serous, with high- 
grade serous accounting for over 90% of serous carcinomas.
Each subtype of ovarian cancer also has characteristic mutations that are 
frequently associated with it. For example, high-grade serous carcinomas often have 
BRCA1 or BRCA2 and TP53 mutations (Gilks and Prat 2009), low-grade serous 
carcinomas are associated with BRAF or KRAS mutations, and clear cell carcinomas 
frequently have PIK3CA mutations. As well, endometrioid carcinomas have the highest 
frequency of CTNNB1 mutations, and mucinous carcinomas are often associated with 
mutations in KRAS (Cho 2009; Gilks and Prat 2009). With respect to prognosis, high- 
grade serous and clear cell are usually associated with a very poor prognosis, while 
endometrioid and mucinous are generally associated with more favourable outcomes 
relative to high-grade serous (Gilks and Prat 2009).
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1.1.5 Progression of epithelial ovarian cancer
During the early stages of EOC progression, tumours are confined to either one, 
or both ovaries (Naora and Montell 2005) (Figure 1.1). The canonical method of 
epithelial cancer metastasis involves the escape o f cells from the primary tumour and the 
intravasation of these cells into the bloodstream, where they travel through the circulation 
and extravásate to metastasize at secondary sites (Chambers, Groom et al. 2002). 
However, unlike most other carcinomas, metastasis of EOC cells through the 
bloodstream is rare (Allen, Porter et al. 1987). Instead, malignant cells are shed from the 
primary tumour directly into the peritoneal cavity as EOC progresses. These cells can 
then exist individually, or as multi-cellular aggregates of EOC cells called spheroids. 
Individual cells and spheroids are both capable of seeding metastases (Zietarska,
Maugard et al. 2007), but spheroid formation is hypothesized to be an intermediate 
survival mechanism for EOC cells during dissemination (Shield, Ackland et al. 2009). 
Once they are shed, EOC cells are transported by peritoneal fluid, and directly 
disseminate throughout the abdominal cavity where they can metastasize to form 
secondary tumours at regional and distant sites (Naora and Montell 2005). Common sites 
of metastasis within the abdominal cavity include the uterus, fallopian tubes, omentum, 
and the diaphragm.
Additionally, the formation of ascites fluid within the abdominal cavity is usually 
associated with this process of peritoneal dissemination (Naora and Montell 2005). The 
buildup o f this fluid contributing to the transportation of EOC cells is thought to be a 
combination of several factors including blockage of the lymphatic system that results in
8
Figure 1.1 Epithelial ovarian cancer metastasis and progression
As ovarian cancer progresses, (A) malignant cells shed from the surface of the ovaries 
directly into fluid within the peritoneal cavity. These cells can either exist as individual 
cells, or can aggregate to form spheroids. The individual cells or spheroids will then be 
transported by ascites fluid throughout the peritoneal cavity where they (B) can form 
secondary métastasés at sites such as the fallopian tubes and omentum (A- adapted from 















decreased fluid drainage, and the production of excess fluid due to inflammation within 
the abdominal cavity.
The mechanisms that control this process of ovarian tumour cell dissemination 
have not been well elucidated, and likely involve a number of different signaling 
pathways. Recently, one such pathway that has been implicated in EOC pathogenesis is 
governed by the bone morphogenetic proteins (BMPs) (Shepherd and Nachtigal 2003).
1.1.6 Treatment of ovarian cancer
The standard treatment for ovarian cancer usually involves cytoreductive 
debulking surgery in combination with adjuvant chemotherapy (Mutch 2002). The 
objectives of cytoreductive surgery are to reduce tumour burden, determine staging, and 
to determine histological subtype. The reduction of initial tumour burden is very 
important in ovarian cancer because it is associated with survival advantages. This is seen 
by the fact that patients with residual tumours that are less than 2 cm have an average 
survival time of 40-45 months, whereas patients with residual tumours that are greater 
than 2 cm have an average survival time of only 12-16 months. After cytoreductive 
surgery, patients are usually treated with intravenous combination chemotherapy of a 
platinum as well as a taxane-containing agent, which is usually carboplatin-paclitaxel 
(Gardner and Jewell 2011). However, the majority of patients will recur within 18 
months (Han, Lin et al. 2009). Recently, phase III clinical trials suggest that 
intraperitoneal administration of platinum-taxane chemotherapy may be more effective 
that intravenous administration (Armstrong, Bundy et al. 2006). As well, neoadjuvant 
chemotherapy can also be administered to patients prior to optimal debulking surgery
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(Bilici, Salepci et al. 2010). The purpose of administering chemotherapy before surgery is 
to reduce tumour burden in order to increase the likelihood of optimal surgical debulking 
and therefore increase median survival time.
The buildup of ascites fluid is another symptom of ovarian cancer that needs to be 
considered in ovarian cancer treatment. This is because recurrent malignant ascites can 
cause painful and unpleasant symptoms that decrease the quality of life of patients, and 
can also cause serious complications such as bowel perforation in extreme cases (Jatoi, 
Giordano et al. 2005). Therefore, repeated paracentesis of ascites fluid from the 
abdominal cavity may be required as often as every 9-10 days (Mackey and Venner 
1996) in order to minimize these symptoms and complications.
Currently, the major focus of clinical trials for ovarian cancer treatment involves 
targeted biologic agents. For example, poly ADP ribose polymerase (PARJP) inhibitors 
such as Olaparib are currently in phase II clinical trials (Audeh, Carmichael et al. 2010). 
As well, the anti-angiogenic agent Bevacizumab that targets the vascular endothelial 
growth factor (VEGF) pathway has demonstrated response benefits to treatment in phase 
III clinical trials (Jelovac and Armstrong 2011).
1.2 The bone morphogenetic protein signaling pathway
1.2.1 Organization of the bone morphogenetic protein signaling family
The transforming growth factor (3 (TGFP) signaling pathway superfamily is 
involved in diverse cellular processes including developmental processes, adult tissue 
homeostasis, and also plays complex roles in many diseases (Moustakas and Heldin 
2009). For example, misregulation of this pathway can result in tumour development
(Massague 2008). The human TGF|3 family consists of 33 members, which are 
subdivided into families (Moustakas and Heldin 2009). These are the TGFp, growth and 
differentiation factor (GDF), activins, nodal, and BMP families of ligands. The BMP 
family is the largest subgroup within the TGFp superfamily of ligands, and contains over 
20 members that have been identified in humans (Blitz and Cho 2009).
Based on their sequence similarities and functions, the BMPs are generally 
divided into at least 4 groups. These groups are BMP 2/4, BMP 5/6/7/8a/8b, BMP 9/10, 
and BMP 12/13/14 (Bragdon, Moseychuk et al. 2011). The BMPs were originally 
identified for their ability to induce ectopic bone and cartilage formation (Blanco Calvo, 
Bolos Fernandez et al. 2009). However, they are involved in many other processes such 
as embryonic patterning and development, tissue homeostasis and regeneration, as well 
as various diseases (Wagner, Sieber et al. 2010). For example, functions that have been 
associated with BMP4 specifically include the formation of teeth, bones, limbs, lungs, 
and eyes from the mesoderm (Thawani, Wang et al. 2010). Additionally, BMP4 is 
involved in dorsal-ventral patterning and craniofacial development, as well as repairing 
bone. Although there is a large degree o f diversity among the functions and expression 
patterns of the BMPs, there are many compensatory functional overlaps (Hebert,
Hayhurst et al. 2003). For example, it has been shown that BMP2 and BMP4 can 
compensate for one another in some aspects of development such as with patterning of 
the dorsal telencephalic midline that eventually gives rise to distinct structures in the 
adult brain in mammals.
The BMPs are expressed in many tissues in human adults. For example, BMP4 
has been shown to be expressed in skeletal muscle, brain, heart, kidney, lung, pancreas,
12
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liver, spinal cord, as well as several other tissues (Bragdon, Moseychuk et al. 2011). With 
respect to the ovaries, BMP4 has been shown to be expressed in almost all major ovary 
cell types including oocyte, granulosa, theca, and ovarian surface epithelium cells 
(Erickson and Shimasaki 2003).
1.2.2 Activation and regulation of bone morphogenetic protein signaling
Of all of the families within the TGFP superfamily, the BMP family is the most 
complex with respect to how it is activated and modulated (Hebert, Hayhurst et al. 2003). 
BMP signaling involves type I (ALK2, ALK3, ALK6) and type II (BMPRII) 
transmembrane serine/threonine kinase receptors (Blanco Calvo, Bolos Fernandez et al. 
2009). In the absence of a signal, these receptors are separated in the plasma membrane. 
The process of BMP signaling begins when a BMP ligand binds to a BMPRII receptor 
(Waite and Eng 2003) (Figure 1.2), which results in the recruitment of a type I receptor to 
form a heteromeric complex. This causes the BMPRII receptor to transphosphorylate the 
type I receptor at its glycine/serine-rich domain, which results in its activation. Once the 
type I receptor is activated, it has the ability to bind to several intracellular proteins that 
are responsible for transducing the signal to the nucleus, which are the Smad proteins.
The activated type I receptor subsequently phosphorylates BMP-specific receptor- 
activated Smads (R-Smads 1, 5, 8), which causes the R-Smad to dissociate from the 
receptor complex into the cytoplasm. The phosphorylated R-Smads can then form homo- 
or heterodimers, and then associate with a common mediator Smad (co-Smad4). Finally, 
the activated R-Smad/Smad4 complex translocates to the nucleus, where it regulates the
14
Figure 1.2 The bone morphogenetic protein signaling pathway
Activation of canonical Smad-dependent BMP signaling begins with the binding of BMP 
ligands to transmembrane receptor complexes. This binding leads to BMP-specific R- 
Smad phosphorylation, formation of an R-Smad/co-Smad4 complex, and translocation of 
this complex to the nucleus where it affects the expression of different target genes 
(adapted from Waite and Eng 2003).
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repressor proteins, and co-activator proteins.
There are several levels at which BMP signaling can be regulated. One way to 
control BMP signaling is through extracellular BMP antagonists such as Noggin,
Chordin, Gremlin, and BMPER (Gazzerro and Canalis 2006). These extracellular 
antagonists bind to BMP ligands and prevent them from binding to type I and type II 
receptors. As well, the synthesis of these BMP antagonists is usually stimulated by BMP 
signaling (Blanco Calvo, Bolos Fernandez et al. 2009), which suggests that there is 
controlled maintenance, i.e. negative-feedback regulation, of the balance of BMPs and 
their antagonists. Each antagonist has different affinities for binding depending on the 
BMP ligand, which allows for complementary functions. Another mechanism of 
inhibiting BMP signaling is through inhibitory Smads 6 and 7 (Imamura, Takase et al. 
1997). These Smads can bind to the type I receptor, and therefore compete with R-Smads 
for activation. Smad6 can also bind to phosphorylated Smadl to prevent it from forming 
a complex with Smad4. Another level of regulation is the pseudoreceptor BMP and 
activin receptor membrane bound inhibitor (BAMBI) (Blanco Calvo, Bolos Fernandez et 
al. 2009). BAMBI is a transmembrane protein that is similar to type I receptors, and 
therefore functions as a decoy receptor to limit signaling. BMP signaling can also be 
regulated by Smad-ubiquitination regulatory factors 1 and 2 (Smurfl and Smurf2), which 
can bind to Smads 1 and 5 in order to initiate proteasomal degradation (Izzi and Attisano 
2004). Finally, transcriptional co-repressors in the nucleus can prevent the activation of 
target genes by BMPs. For example, c-Ski is a transcriptional co-repressor that can be 
incorporated into Smad DNA binding complexes, which prevents them from interacting
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with co-activators and initiating the transcription of target genes (Akiyoshi, Inoue et al. 
1999).
Although these descriptions of BMP signaling involving the Smad proteins is the 
canonical and most studied aspect of the BMP signaling pathway, BMPs can also induce 
Smad-independent signaling. For example, BMP signaling has been shown to induce p38 
mitogen-activated protein kinase (p38 MAPK) phosphorylation (Nakamura, Shirai et al. 
1999), extracellular signaling regulated kinase (ERK) activation (Montesano 2007), c-Jun 
N-terminal kinase (JNK) activation (Hocevar, Brown et al. 1999), and protein kinase C 
(PKC)-dependent pathway activation (Hay, Lemonnier et al. 2001). Conversely, the R- 
Smads and Smad4 can be activated by kinases in other pathways such as Erkl and Erk2, 
p38, and JNK (Blanco Calvo, Bolos Fernandez et al. 2009).
One of the transcription factor families that has been established as BMP- 
regulated target genes are the inhibitors o f DNA binding (ID) proteins, of which there are 
4 known members of this family (ID1-ID4) (Pesce and Benezra 1993). All of the ID 
family members contain a highly conserved helix-loop-helix domain that mediates 
physical interactions with basic helix-loop-helix (bHLH) transcription factors that control 
gene expression (Benezra, Davis et al. 1990). Since the IDs do not have a DNA binding 
domain, heterodimeric complexes that are formed between the IDs and transcription 
factors cannot bind DNA. Therefore, these proteins can have a significant regulatory 
effect on gene expression. These proteins are known to play important roles in 
embryogenesis and organogenesis (Lyden, Young et al. 1999), cell differentiation and 
proliferation (Norton 2000), control of cell cycle progression, apoptosis (Norton and 
Atherton 1998), and angiogenesis (Benezra, Rafii et al. 2001). As well, there are
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functional redundancies and some similar temporal and spatial expression patterns among 
the 4 ID proteins (Norton 2000). In the adult, these proteins are expressed at low levels in 
normal tissues, but their expression is often deregulated in tumours (Mem, Hasskarl et al. 
2010). For example, the IDs have been shown to be upregulated in several human cancers 
such ovarian (Shepherd and Nachtigal 2003), lung (Cheng, Tsai et al. 2011), prostate 
(Forootan, Wong et al. 2007), and breast cancers (Yang, Liu et al. 2010).
1.2.3 Bone morphogenetic protein signaling in cancer
Although many of the BMPs have been implicated in the promotion or inhibition 
of cancer development (Thawani, Wang et al. 2010), I will be focusing on studies 
involving BMP4, and to a lesser extent, its subfamily member BMP2. There are several 
lines of evidence in vitro and in vivo attributing pro-tumourigenic as well as anti- 
tumourigenic properties to BMP4 in numerous types of cancer. BMP4 is overexpressed 
in many cancers such as melanoma (Rothhammer, Poser et al. 2005), hepatocellular 
carcinoma (Maegdefrau, Amann et al. 2009), colon adenocarcinoma (Deng, Makizumi et 
al. 2007), and multiple myeloma (Grcevic, Kusec et al. 2010). However, BMP4 has been 
shown to exhibit decreased expression relative to normal tissues in cancers such as 
prostate cancer (Spanjol, Djordjevic et al. 2010), and retinoblastoma (Haubold, Weise et 
al. 2010).
There is a large body of evidence in vitro suggesting that BMP4 signaling 
increases cancer cell proliferation, increases migration, increases invasion, decreases 
apoptosis, and induces expression of EMT markers. Treatment of the human DAOY 
cerebellar primitive neuroectodermal tumour medulloblastoma cell line with either BMP2
or BMP4 induced an anti-apoptotic effect based on immunohistochemistry (Iantosca, 
McPherson et al. 1999). In other studies, tissue sections of osteosarcomas that were 
removed from patients were evaluated to look at BMP2 and BMP4 expression (Arihiro 
and Inai 2001). It was found that BMP2 and BMP4 expression strongly correlated with 
the tendency of these tumours to metastasize to bone in patients. Abnormal duct 
organization and ductal lumen obliteration represent some of the early stages of breast 
cancer progression. When mouse J3B1A mammary epithelial cells were treated with 
BMP4, they were unable to form any recognizable ductal lumen, thus contributing to the 
tumourigenic progression of these cells (Montesano, Sarkozi et al. 2008). Another study 
using J3B1A cells has shown that treatment with BMP4 significantly increases 
proliferation (Montesano 2007). Similarly, GH3 prolactinoma cells that were treated with 
BMP4 exhibited increased cell proliferation (Paez-Pereda, Giacomini et al. 2003). The 
expression of c-Myc oncoprotein was also increased in these BMP4-treated GH3 cells, 
while treatment with the BMP inhibitor noggin decreased proliferation and expression of 
c-Myc. In human LAPC-4 and LAPC-9 prostate cancer cells, treatment with noggin 
resulted in decreased cell migration (Feeley, Gamradt et al. 2005). A study involving NCI 
H929 and Thiel human myeloma cell lines investigated the role of BMP4 signaling in 
apoptosis (Grcevic, Kusec et al. 2010). These cell lines were treated with the proteasome 
inhibitor Bortezomib alone or in combination with BMP4. Results demonstrated that cells 
treated with BMP4 were partially protected from the apoptotic effects induced by 
Bortezomib. BMP4 also has an important role in tumourigenesis in hepatocellular 
carcinoma (HCC). The HepG2, Hep3B, and PLC human HCC cell lines in addition to 
primary human HCC cells isolated from patients were transfected with antisense BMP4
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expression plasmids or siRNA against BMP4 (Maegdefrau, Amann et al. 2009). 
Knockdown of BMP4 resulted in a decrease in both cell migration and invasion through 
Matrigel. With respect to the Panc-1 human pancreatic cancer cell line, treatment with 
BMP4 induces epithelial-mesenchymal transition (EMT) (Hamada, Satoh et al. 2007). 
This was seen by the fact that these treated cells exhibited decreased expression of E- 
cadherin, and increased expression of vimentin. It was suggested that these effects on 
EMT induction are mediated through an increase in homeobox gene transcription factor 
MSX2 expression. MSX2 has been previously shown to be a target gene of BMP 
signaling (Hussein, Duff et al. 2003), and enhances EMT in pancreatic cancer cells 
(Satoh, Hamada et al. 2008). Additionally, these BMP4-treated Panc-1 cells had 
enhanced cell motility (Hamada, Satoh et al. 2007). HCT116 human colorectal cancer 
cell line clones have also been transfected with BMP4 over-expression plasmid (Deng, 
Makizumi et al. 2007). These BMP4 overexpressing clones show increased resistance to 
serum-starving induced apoptosis (Deng, Makizumi et al. 2007). These cells also 
displayed enhanced migration and invasion through Matrigel. Noggin treatment reversed 
all of these tumourigenic effects in HCT116 cells. Another study examining human 
colorectal cancer by using the SW480 cell line shows that the stable transfection of 
BMP4 plasmid in these cells results in the upregulation of vimentin expression (Deng, 
Ravikumar et al. 2009).
These pro-tumourigenic effects of BMP signaling have also been assessed in vivo. 
For example, GH3 prolactinoma cells that were stably transfected with noggin and 
injected into nude mice formed tumours that were smaller based on volume, and these 
tumours also had reduced c-Myc oncoprotein expression (Paez-Pereda, Giacomini et al.
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2003). Additionally, studies subjected SCID mice to tibial injections with LAPC-9 
prostate cancer cells that were transduced with retrovirus that contained noggin-cDNA 
(Feeley, Gamradt et al. 2005). Mice that were injected with these noggin-overexpressing 
LAPC-9 cells formed significantly smaller osteoblastic lesions when viewed on 
radiographs (Feeley, Gamradt et al. 2005).
There is a growing body of evidence in vitro suggesting that the BMPs, 
particularly BMP4, play important roles as tumour suppressors. For example, treatment 
with BMP2 or BMP4 inhibits proliferation of mouse cerebellar granule neuron progenitor 
(GNP)-like medulloblastoma cells (Zhao, Ayrault et al. 2008). The effects of BMP2 and 
BMP4 treatment have also been evaluated in primary human glioblastoma (GBM) cells. 
Treatment with BMP2 or BMP4 did not induce cell death or apoptosis in vitro in these 
cells (Piccirillo, Reynolds et al. 2006). However, BMP4 treatment, and to a lesser extent 
BMP2 treatment, significantly decreased the proliferation of GBM cells. Relative to non- 
treated cells, BMP treatment also led these cells to become more differentiated as seen by 
cell morphology and increases in the fluorescence signaling intensity of glial fibrillary 
acidic protein (GFAP). In another study, human glioma U251 cells that were transfected 
with BMP4 plasmid exhibited decreased proliferation (Liu, Tian et al. 2010). Upon 
BMP4 treatment of 9 different breast cancer lines, all cell lines exhibited significant 
growth inhibition relative to vehicle-treated cells (Ketolainen, Alarmo et al. 2010) 
(Ketolainen, Alarmo et al. 2010). Another study that investigated the relationship 
between BMP signaling and breast cancer used MDA-MB-231 breast cancer cells, and 
treatment of these cells with BMP4 resulted in a significant decrease in the migratory and 
invasive abilities of these cells (Shon, Kim et al. 2009). These effects were likely
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mediated through decreased mRNA expression of matrix metalloproteinase 9 (MMP 9), 
which is an enzyme that is in part responsible for the degradation of surrounding 
extracellular matrix components during invasion and metastasis. Treatment of human 
A549 epithelial ling cancer cells with BMP4 led to a more senescent phenotype (Buckley, 
Shi et al. 2004). In another study involving A549 lung cancer cells, BMP4-treatment led 
to decreased p-ERK and Bcl2, supporting decreased proliferation and increased potential 
for apoptosis, as well as decreased invasiveness. Similarly, studies with siRNA-mediated 
knockdown of BMP4 in A549 and NCI-H460 non-small cell lung cancer cells showed 
increased proliferation, as well as decreased senescence (Su, Zhu et al. 2009). Treatment 
with exogenous BMP4 decreased proliferation and increased apoptosis in ANBL-6, OH2, 
and IH1 human myeloma cell lines (Hjertner, Hjorth-Hansen et al. 2001). In this same 
study, freshly isolated primary multiple myeloma cancer cells from several patients that 
were immediately treated with BMP4 exhibited increased apoptosis. Treatment of 8 
retinoblastoma cell lines with recombinant human BMP4 results in an increase in 
apoptosis (Haubold, Weise et al. 2010). Also, primary human basal cell carcinoma (BCC) 
cells that were isolated from patient tumours and subsequently treated with recombinant 
human BMP4 exhibited decreased cell proliferation (Sneddon, Zhen et al. 2006). 
Similarly, primary human BCC cells in this study that were treated with recombinant 
mouse BMP inhibitor Gremlin-1 exhibited increased cell proliferation. Using human 
AtT-20 pituitary corticotroph tumour cells, it was shown that treatment with BMP4 
inhibited cell proliferation (Giacomini, Paez-Pereda et al. 2006). Finally, human 
NTERA2 teratocarcinoma cells that were treated with exogenous BMP4 exhibited a 
decrease in cell proliferation and increased apoptosis (Nishanian, Kim et al. 2004).
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There has also been a small number of studies in vivo supporting BMP signaling 
as an anti-tumourigenic pathway. For example, mouse cerebellar GNP-like 
medulloblastoma cells were transfected with BMP4 and were allografted into 
immunocompromised athymic mice (Zhao, Ayrault et al. 2008). Tumours formed in these 
mice were much smaller than allografts o f cells transfected with a control vector. When 
BMP4-saturated polyacrylic beads where co-injected with GBM cells into mice, the mice 
developed smaller, more confined lesions, and survived for a significantly longer period 
of time compared to controls (Piccirillo, Reynolds et al. 2006). Another study showed 
that BMP4-treated A549 cells that were injected into nude mice formed much smaller 
tumours based on volume (Buckley, Shi et al. 2004). Also, stably transfecting human 
AtT-20 pituitary corticotroph tumour cells with expression vectors for noggin or a 
dominant-negative form of BMP4 and injecting them into nude mice corresponded to 
increased tumourigenicity as measured by tumour volume (Giacomini, Paez-Pereda et al. 
2006). Finally, BMP4-treated human NTERA2 cells that were injected into 
immunodeficient mice formed smaller tumours relative to controls based on tumour 
volume (Nishanian, Kim et al. 2004).
BMP4 has recently been shown to have an effect on cancer stem cells, or cancer 
initiating cells. One study used primary colorectal cancer stem cells (CRC-SCs) that were 
selected from primary patient tumour samples based on CD 133 expression (Lombardo, 
Scopelliti et al. 2011). Although BMP4 is usually expressed in colorectal cancer, it was 
not detected in the CRC-SCs (Lombardo, Scopelliti et al. 2011). In vitro, CRC-SCs form 
spheres of aggregated cells, whereas differentiated colorectal cancer cells lack this 
ability. Treatment of CRC-SCs with exogenous BMP4 induced cell differentiation based
on immunohistochemical staining for the expression of CK20+ cells. Phase contrast 
microscopy also confirmed that these cells differentiated as evidenced by larger, 
polygonal colon cells. The effect of BMP4 treatment on CRC-SC response to 
chemotherapy was also evaluated. Tumours that were formed in immunocompromised 
mice by CRC-SC sphere injections were treated with oxaliplatin and 5-fluorouracil (5- 
FU) alone or in combination with BMP4-loaded heparin acrylic beads. Combination 
treatment with BMP4 sensitized the tumours to chemotherapy as measured by tumour 
size after treatment. Also, another study investigated the role of BMP4 in brain tumour- 
initiating cells (BTICs) of human GBMs (Piccirillo, Reynolds et al. 2006). Treatment of 
primary adult human GBM cells with exogenous BMP4 significantly reduced the pool of 
BTICs by approximately 50% in GBM cell populations as measured by sorting for 
CD133+ cells from culture.
Overall, these differing and often contrasting reports on the numerous roles of 
BMP4 in cancer highlight the fact that BMP signaling may have unique roles in the 
process of tumourigenesis on a cancer-specific basis. Additionally, BMP signaling may 
have different roles even within the same type of cancer depending on the stage of the 
disease. Therefore, it is essential to study the roles of BMP4 signaling in an EOC-specific 
context.
1.2.4 Bone morphogenetic protein signaling in ovarian cancer
It has been shown that immortalized normal OSE cells, ovarian cancer cell lines, 
primary normal OSE cells, and primary EOC cells all express BMP4 mRNA (Shepherd 
and Nachtigal 2003). However, BMP2 was expressed in a smaller number of samples,
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and BMP7 was not expressed in any sample. Mature BMP4 protein was also expressed in 
primary EOC cells as measured by immunoprécipitation of 35S-Met/Cys radiolabeled 
BMP4 proteins that were secreted by cells into culture medium. Additionally, all of the 
samples expressed the intracellular components that are necessary for a functional BMP4 
signaling pathway based on mRNA expression. These included type II BMP receptors, as 
well as type I BMP ALK3 receptors. Type I BMP ALK6 receptors were expressed in the 
EOC cell lines, but expression was very weak or absent in the primary and immortalized 
cells. In addition, each group of cells expressed co-Smad4, and R-Smads 1, 5, and 8.
Not only are components of BMP4 signaling present in EOC and OSE cells, but 
the pathway is also functional (Shepherd and Nachtigal 2003). This was assessed by 
treating cells in vitro with recombinant human BMP4. BMP4 treated cells expressed 
increased phospho-Smadl and had enhanced nuclear localization of phospho-Smadl 
based on indirect immunofluorescence. BMP-regulated target genes Smadô, Smad7, ID1, 
and ID3 RNA were all induced by BMP4 treatment. Interestingly, ID1 and ID3 
expression were induced approximately 5 fold more in BMP4-treated primary EOC cells 
relative to induction in BMP-treated normal OSE cells. A similar study has shown that 
treatment of CaOV3 human ovarian cancer cells with noggin resulted in a decrease in 
endogenous ID3 mRNA expression in a dose-dependent manner (Shepherd, Theriault et 
al. 2008). However, treatment of these cells with broader BMP inhibitors that have a 
weaker affinity for BMP4 did not significantly change ID3 expression, which suggests 
that ID3 overexpression in human EOC is controlled primarily by autocrine BMP4 
signaling.
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The CaOV3 and SkOV3 human ovarian cancer cell lines in addition to primary 
EOC cells that were isolated from ascites fluid were all treated with recombinant human
BMP4. With respect to proliferation, BMP4 treatment had no effect (Shepherd and 
Nachtigal 2003). However, BMP4 treatment led to changes in cell morphology that 
resembled cell spreading and cells appeared more flattened as opposed to the epithelial- 
like cobblestone morphology that was representative of untreated cells (Shepherd and 
Nachtigal 2003; Theriault, Shepherd et al. 2007). As well, primary human ovarian cancer 
cells and normal OSE cells were treated with human recombinant BMP4 or transduced 
with an adenovirus expressing constitutively active ALK3 (ALK3QD). These cells were 
significantly larger in size with respect to area relative to untreated cells based on phase- 
contrast images (Theriault, Shepherd et al. 2007). One of the functional implications of 
this cell spreading morphology was seen by the fact that BMP4 treatment led to 
decreased cell detachment in vitro (Shepherd and Nachtigal 2003). Additionally, primary 
EOC cells that were treated with BMP4 or transduced with ALK3QD showed increased 
motility (Theriault, Shepherd et al. 2007). Conversely, treatment of these cells with 
noggin decreased cell motility. However, treatment of normal OSE cells with BMP4 did 
not affect motility, which suggests that EOC cells have enhanced their motility in 
response to acquired autocrine BMP signaling. As well, primary EOC cells that were 
transduced with ALK3QD exhibited an increase in invasive potential in vitro. After 
BMP4 treatment, primary EOC cells exhibited increased expression of Snail and Slug 
protein. These EMT marker proteins are known to repress E-cadherin (Batlle, Sancho et 
al. 2000), which exhibited decreased protein expression in BMP4 treated cells. This 
suggests that BMP4 can induce EMT in primary EOC cells (Theriault, Shepherd et al.
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2007). Another study has shown that chordin is underexpressed in EOC tumour samples 
relative to normal ovarian tissue at the mRNA level (Moll, Millet et al. 2006). After this 
discovery, BG1 and PE014 human ovarian cancer cell lines were transiently transfected 
with an expression vector for chordin. This chordin overexpression decreased the 
migration and invasion capabilities of these cells. Additionally, chordin treatment 
increased the adhesion of EOC cells.
Studies have also implicated BMP signaling in decreasing metastatic potential in 
ovarian cancer. For example, OVCA429 human ovarian cancer cells were transfected for 
doxycycline-inducible expression of constitutively-active ALK3QD in order to evaluate 
the role of BMP signaling in ovarian cancer metastasis (Shepherd, Mujoomdar et al. 
2010). Xenografts of these OVCA429 ALK3QD induced clones into athymic nude mice 
resulted in decreased tumour implantation on peritoneal surfaces. As well, these mice 
exhibited a decrease in ascites formation. A potential underlying basis for this decrease in 
metastatic potential was that pi-integrin and p3-integrin mRNA expression was 
decreased in ALK3QD-expressing cells. These integrin proteins are essential for cell 
adhesion, and in fact, ALK3QD-expressing cells exhibit reduced cell adhesion to 
fibronectin and vitronectin in vitro. Additionally, OVCA429 ALK3QD-expressing cells 
had reduced cell cohesion based on their decreased ability to form spheroids in ultra-low 
attachment plates as measured by decreased size and density of the spheroids in culture. 
Overall, this paper suggested that although upregulated BMP signaling is advantageous 
for cells to lose adhesion and exfoliate from the primary tumour, decreased BMP 
signaling may be important for cells to metastasize and adhere to secondary tumour sites. 
In an expression study involving BMP2, it was shown that this protein in addition to
BMPR1B and BMPRII was expressed at lower levels in ovarian cancer tumours 
compared to normal ovarian tissue (Ma, Ma et al. 2010). Additionally, retrospective 
analyses were completed in which tumour sections obtained from patients were stained 
for BMP2 and evaluated using immunohistochemistry. A correlation was found 
suggesting that patients with positive expression of BMP2 in tumours had a significantly 
increased average 5-year survival rate relative to patients with tumour samples that did 
not stain for BMP2. Studies investigating the role of BMP signaling in ovarian cancer 
have also focused on antagonists of this pathway. For example, SKOV3 human ovarian 
cancer cells were transfected with a vector expressing BAMBI, which is a BMP type I 
pseudoreceptor (Pils, Wittinger et al. 2010). Upregulated BAMBI expression in these 
cells led to increased cell proliferation as measured in vitro.
Human ovarian carcinoma-associated mesenchymal stem cells (CA-MSCs) have 
recently been identified and characterized (McLean, Gong et al. 2011). Upon 
subcutaneous injections of human ovarian cancer SKOV3 cells alone or in combination 
with either CA-MSCs or healthy donor MSCs into immune-compromised mice, co­
injection with CA-MSCs significantly increased tumour size based on weight. As well, 
culturing ovarian tumour cells in the presence of CA-MSCs resulted in the tumour cells 
forming large spheroids in vitro, which is associated with cancer stem cells (CSCs)
(Ernst, Hofmann et al. 2009). Interestingly, BMP2 and BMP4 mRNA were significantly 
upregulated in all human CA-MSC samples (McLean, Gong et al. 2011). Inhibition of 
BMP signaling with noggin decreased tumour spheroid formation, and prevented CA- 
MSC cells from stimulating ovarian tumour growth in mice.
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1.2.5 Bone morphogenetic protein signaling and angiogenesis
Angiogenesis is one of the hallmarks of cancer along with uncontrolled 
proliferative signaling, reprogramming of energy metabolism, evasion of growth 
suppression, resistance to cell death, evasion of immune destruction, replicative 
immortality, and the activation of invasion and metastasis capabilities (Hanahan and 
Weinberg 2011). In addition to normal tissues, tumours require access to a blood supply 
in order to receive oxygen and nutrients, and to excrete waste products and carbon 
dioxide. During embryonic development, blood vessels can form through one of two 
processes (Hanahan and Folkman 1996). The first process is vasculogenesis, which 
involves the formation of new blood vessels through the creation of new endothelial cells 
from progenitor cells. The second process is angiogenesis, which involves the sprouting 
of new capillaries from pre-existing blood vessels. In the adult, new blood vessel 
formation is accomplished predominantly through the process of angiogenesis.
With the exception of transient processes such as wound healing and the female 
reproductive cycle, vasculature in the adult is usually in a quiescent state (Hanahan and 
Weinberg 2011). However, the vasculature remains activated during tumour development 
throughout the process of angiogenesis in order for tumours to be able to survive and 
grow beyond 1 -2 mm in diameter (Bergers and Benjamin 2003). This change in 
vasculature activity is termed the angiogenic switch, which describes a change in the 
balance between angiogenic promoters such as VEGF, and angiogenic inhibitors such as 
thrombospondin-1 (TSP-1) (Hanahan and Folkman 1996).
Interestingly, the blood vessels that are formed by angiogenesis during 
tumourigenesis differ from blood vessels formed under normal conditions because they
are irregularly shaped and disorganized, unusually large, have extensive branching, and 
display leakiness (Nagy, Chang et al. 2010). Briefly, this process of angiogenesis in 
tumours begins with endothelial cells releasing factors that degrade the basement 
membrane of the vessel walls (Hanahan and Folkman 1996). The endothelial cells near 
this area of membrane degradation then invade the surrounding stroma and proliferate as 
a migrating column. Then, these endothelial cells will strop proliferating and differentiate 
so that they are able to tightly adhere to each other and form a new capillary tube.
The BMP signaling pathway has been shown to be essential in the processes of 
vasculogenesis and angiogenesis, with BMP2 and BMP4 appearing to be the most 
important members of the BMP family in this process as evidenced by mouse knockout 
models (Moser and Patterson 2005). Mouse embryos with inactivated BMP4 display 
defects in mesoderm formation, which is required for vascular development, and most 
mice die around embryonic day (E)7.5 (Winnier, Blessing et al. 1995). Some of these 
mice survive until approximately E9.5, but eventually die and exhibit abnormal 
vasculature with a reduced number of blood islands. ALK2-deficient mouse embryos die 
early in development with severe disruption of mesoderm formation that is essential in 
the formation of mature vasculature (Gu, Reynolds et al. 1999). ALK3-deficient mouse 
embryos exhibit similar characteristics, and die early in development due to a lack of 
mesoderm formation (Mishina, Suzuki et al. 1995). As well, mice with heterozygous 
inactivating mutations of BMP type 2 receptor have an impaired ability to remodel 
vasculature in response to exposure to prolonged hypoxia (Beppu, Ichinose et al. 2004). 
The Smads have also been shown to play an important role in angiogenesis during mouse 
embryonic development. For example, Smadl null mice die during gestation in part due
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to vascular disorganization (Lechleider, Ryan et al. 2001), and mice in which Smad5 is 
inactivated die during gestation due to vasculature defects and irregular distribution of 
blood cells (Yang, Castilla et al. 1999). Additionally, Smad4 deficient mice die by E6.5 
due to a lack of mesoderm formation (Sirard, de la Pompa et al. 1998). Transcription 
factors that are targeted by BMP signaling have also been investigated in knockout mice. 
For example, double knockout IDF'' ID3'/_ mice die before E l3.5 (Lyden, Young et al.
1999). Blood vessels in these mice are unable to branch or sprout into the neuroectoderm, 
and also have defects in the vasculature within the forebrain.
It has been shown both in vitro and in vivo that human endothelial cells involved 
in blood vessel formation possess an intact and functional BMP signaling pathway, and 
there is direct evidence that BMP signaling plays a role in the process of angiogenesis 
(Valdimarsdottir, Goumans et al. 2002). Using Matrigel tube formation angiogenesis 
assays with human microvascular endothelial cells (HMECs), it was shown that BMP4 
enhanced angiogenesis (Rothhammer, Bataille et al. 2007). In mouse osteoblast cells, 
exogenous treatment of BMP4 in vitro induced angiogenesis due to an increase in VEGF- 
A protein production (Deckers, van Bezooijen et al. 2002). However, BMP4-induced 
angiogenesis treatment was abrogated when VEGF-A antibody was added to these 
osteoblast cells, suggesting that BMP4-induced angiogenesis is mediated in part by 
VEGF-A. Ectopic BMP4 signaling in zebrafish embryos induced the expression of 
VEGF and VEGF receptor 2 mRNA in embryonic endothelial and blood precursor cells 
(He and Chen 2005). As well, treatment of human retinal pigment epithelial cells with 
BMP4 led to an increase in VEGF secretion in a dose and time-dependent manner (Vogt, 
Unda et al. 2006). Transient transfections of endothelial cells from human colon, mouse
aorta, and mouse heart with constitutively-active ALK3, Smadl, or Smad5 were shown 
to stimulate cell migration and tube formation (Valdimarsdottir, Goumans et al. 2002). 
Interestingly, ectopic expression of Idl also stimulated tube formation, while treatment 
with antisense Idl blocked the BMP-induced effects on tube formation. Other than VEGF 
and Idl, relatively little is known about downstream target genes that are affected by 
BMP signaling that have a role in angiogenesis (Ren, Charles et al. 2007). Recently, gene 
expression profiling of BMP-treated mouse intraembryonic endothelial cells highlighted 
Cox2 as a gene that is strongly upregulated by BMP stimulation. Inhibition of Cox2 
blocked the BMP-induced increases in endothelial cell proliferation and tube formation. 
Similar microarray studies have also shown that MyolO is strongly upregulated in BMP- 
treated mouse endothelial cells, with inhibition of MyolO decreasing BMP-induced tube 
formation on Matrigel (Pi, Ren et al. 2007).
Although these studies highlight a role for BMP signaling in the activation of 
angiogenesis, there are also several conflicting reports that implicate BMP signaling in 
the inhibition of angiogenesis. In a mouse model where retina were subjected to hypoxia 
in order to stimulate neovascularization, BMP4-mRNA expression was drastically 
decreased (Mathura, Jafari et al. 2000). Likewise, primary cultures of human retinal 
pericytes exhibited increased expression of BMP4 antagonist chordin-like 1 mRNA in 
response to hypoxia. Angiogenesis assays using human umbilical vein endothelial cells 
(HUVECs) were done using exogenous BMP4 alone, exogenous chordin-like 1 alone, or 
in combination. BMP4 treatment significantly inhibited angiogenesis (Kane, Godson et 
al. 2008). While chordin-like 1 did not have a significant effect on its own, it modulated 
the inhibitory effect of BMP4 on angiogenesis when added in combination. BMP4
signaling has also been implicated in studies in vivo looking at the process of 
microvascular remodeling, which includes the formation of new blood vessels as well as 
the regression of others. When BMP4 was injected transcomeally into postnatal day 8 
rats, the number of apoptotic endothelial cells was significantly increased in dissected 
pupillary membranes (Kiyono and Shibuya 2003). Conversely, the addition of noggin or 
BMP4-specific neutralizing antibody increased the number of surviving capillary cells by 
4-6 fold. BMP4 has also been shown to induce apoptosis of primary human capillary 
venous endothelial cells in a dose-dependent manner in vitro (Kiyono and Shibuya 2006). 
However, human arterial endothelial cells were not affected by BMP4 treatment initially. 
Interestingly, mRNA levels of inhibitory Smads 6 and 7 were strongly correlated with 
BMP4-induced apoptosis resistance in these cells, and knockdown of inhibitory Smad 
expression with siRNA caused sensitization of endothelial cells to BMP4 stimulation.
BMP antagonists have also been implicated in angiogenesis. Increasing doses of 
BMPER increased HUVEC sprouting, which was inhibited when BMPER was silenced 
(Heinke, Wehofsits et al. 2008). These results were also confirmed with in vivo 
experiments where BMPER protein addition to the surface of the chick chorioallantoic 
membrane (CAM) increased the density o f the capillary network and average diameter of 
blood vessels. As well, using a subcutaneous mouse Matrigel plug assay, increased 
BMPER enhanced endothelial cell invasion. Interestingly, BMPER lost its proangiogenic 
capacity at higher concentrations both in vitro and in vivo, which suggests the presence of 
a feedback mechanism to modulate endothelial cell functions in a dose-dependent 
manner, or off-target effects such as the inhibition of additional low-affinity ligands. 
Another BMP antagonist, Gremlin, has been shown to increase blood vessel formation in
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vivo when gelatin sponge implants containing Gremlin were placed on the surface of the 
chick CAM (Mitola, Moroni et al. 2008). Specifically, Gremlin induces angiogenesis by 
inducing angiopoietin-1 expression in endothelial cells through the activation of NF-kB.
1.2.6 Bone morphogenetic protein signaling and tumour angiogenesis
With respect to tumour growth, the BMPs have been implicated in enhancing 
angiogenesis in several different types of cancer. BMP2 has been the most extensively 
studied with respect to the role of BMPs in angiogenesis and tumour formation 
(Langenfeld and Langenfeld 2004; Raida, Clement et al. 2005; Bieniasz, Oszajca et al. 
2009). For example, co-injection of A549 lung cancer cells and recombinant BMP2 into 
athymic nude mice resulted in the formation larger tumours that had a significant increase 
in the number of blood vessels relative to control injections (Langenfeld and Langenfeld 
2004). The inhibition of BMP2 signaling with noggin or BMP2 antisense 
oligonucleotides resulted in decreased blood vessel formation in these tumours. Similar 
effects of BMP2 have been observed in breast cancer, as athymic nude mice that were 
injected with BMP 2 stably-transfected MCF-7 human breast cancer cells exhibited 
developed tumours with high vascularization (Raida, Clement et al. 2005). Furthermore, 
it was shown in this study that BMP2 upregulates p38 MAPK phosphorylation and Idl 
expression in HUVECs, which suggests potential mechanisms by which BMP2 can 
achieve its effects on tumour angiogenesis. As well, it has been shown that BMP2 mRNA 
is positively correlated with VEGF mRNA in lung cancer patients (Bieniasz, Oszajca et
al. 2009).
BMP4 has also been shown to play a role in tumour angiogenesis. Mel Im 
melanoma cells that were stably transfected with antisense BMP4 or noggin expression 
vector had a decreased ability to induce endothelial cell tube formation (Rothhammer, 
Bataille et al. 2007). As well, when these transfected cells were injected into athymic 
nude mice, resultant tumours had a decrease in blood vessel density. In Hep3 human 
HCC cells, BMP4 expression was significantly increased when hypoxia was induced in 
vitro (Maegdefrau, Amann et al. 2009). Additionally, HCCs that were transfected with 
siRNA against BMP4 and co-cultured with HMECs resulted in a significantly decreased 
ability to induce angiogenesis.
The role of the BMP signaling pathway has also been assessed indirectly in Id l+/" 
Id3’/_ mice. In these mice, reduced Id expression resulted in small tumour growth from 
injected breast cancer cells, and these tumours regressed within 2 weeks relative to the 
much larger tumours that were formed in wild-type mice (Lyden, Young et al. 1999). 
Tumour growth in Id l+/' Id3 was intermediate between wild-type and Id l+/' I d 3 mi c e ,  
clearly indicating a dose-dependency of Id protein function on tumour angiogenesis. 
These results were consistent for injections of B6RV2 lymphoma cells, and B-CA breast 
cancer cells into Id-deficient mice where differences in tumour growth were attributed to 
poor vascularization due to decreased branching and sprouting of blood vessels compared 
to wild-type mice.
Due to numerous studies that have been discussed above implicating BMP 
signaling in tumour angiogenesis, components of the BMP signaling pathway have been 
established as potential targets for anti-angiogenic therapy in some cancers. For example, 
the heparin sulfate proteoglycan mimetic drug WSS25 has been shown to inhibit human
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microvascular endothelial cell tube formation in Matrigel angiogenesis assays (Qiu, Yang 
et al. 2010). Mechanistically, WS225 was shown to exert its effects by blocking 
BMP2/Smad/Idl signaling. This result was confirmed in vivo, as WSS25 treatment of 
nude mice that were injected with hepatocellular carcinoma cells exhibited decreased 
tumour growth due to the inhibition of angiogenesis.
In rare instances, BMPs have been shown to either have no effect on 
angiogenesis, or decrease angiogenesis in tumours. For example, there was no significant 
difference in VEGF and IL-8 expression levels upon recombinant human BMP2 
treatment of UMSCC-1 and UMSCC-74A human oral squamous cell carcinoma (OSCC) 
cells (Gao, Tong et al. 2010). This result was confirmed in vivo, as there was no 
difference in blood vessel density of OSCC tumours formed from cells that were infected 
with adenovirus expressing BMP-2 before being injected into mice. Also, treatment of 
A549 lung carcinoma cells with BMP4 in vitro led to decreased expression of VEGF 
protein, which contributed to the formation of smaller tumours that were formed in nude 
mice (Buckley, Shi et al. 2004). Additionally, the BMP antagonist gremlin is believed to 
play a pro-angiogenic role in specific cancers. For example, injection of human 
adenocarcinoma HEC-l-B cells into nude mice showed very strong gremlin expression in 
highly vascularized areas of the tumour, whereas expression was much lower in other 
parts of the tumour (Stabile, Mitola et al. 2007). Despite the fact that the majority of the 
current literature supports the BMPs as pro-angiogenic factors with respect to 
tumourigenesis, these examples of BMPs having anti-angiogenic effects highlight the 
importance of studying BMP signaling relating to tumour angiogenesis in a cancer- 
specific context. Specifically, the role of BMP signaling in angiogenesis has never been
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reported in EOC. Therefore, our findings will shed light on the potentially unique role of 
BMP4 signaling on mouse EOC angiogenesis.
1.3 Models of cancer
1.3.1 Mouse models of epithelial ovarian cancer
Although there have been other animal models such as rat (Davies, Auersperg et 
al. 1998), rabbit (Coppola, Saunders et al. 1999), and hen (Johnson 2009) models of 
ovarian cancer, this discussion will focus on mouse models of EOC. Historically, the 
majority of animal models of ovarian cancer have involved xenografting human ovarian 
cancer cells into immunodeficient mice such as severe combined immunodeficient 
(SCID) and athymic nude mice (Cho 2009). These xenografts have been administered by 
subcutaneous implantation (Downer, Jones et al. 2001), intraperitoneal injections 
(Shepherd, Mujoomdar et al. 2010), and by orthotopic implantations into the mouse 
ovarian bursa (Greenaway, Henkin et al. 2009).
Alternatively, mouse cell lines were created from studies in which mouse ovarian 
surface epithelial cells were passaged repeatedly in vitro. Late passage cells then 
spontaneously transformed and were able to form ovarian tumours when injected into 
both immunocompromised and immunocompetent mice (Roby, Taylor et al. 2000). From 
this study, the spontaneously-transformed clone ID8 has been generated, which has been 
shown to express constitutively active Src (Pengetnze, Steed et al. 2003). There is another 
mouse ovarian cancer cell line that has been created by transfecting SV40 TAg into 
primary cultures of mouse ovarian surface epithelium (MOSE) cells, which were then 
able to form tumours when injected into nude mice (Kido and Shibuya 1998). However,
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additional mouse EOC cell lines with specific and known mutations need to be created 
and characterized so that they can be used in order to gain a more thorough understanding 
of EOC.
There have been some recently developed genetically engineered mouse models 
of EOC. One of the first transgenic mouse models of EOC was created by expressing the 
early region of the SV40 TAg gene, and placing it under the transcriptional control of the 
MISRII (Müllerian inhibiting substance type II receptor) gene promoter (Connolly, Bao et 
al. 2003). These TgMISIIR-TAg transgenic mice develop poorly differentiated ovarian 
cancer that replicates several key features of human ovarian cancer progression such as 
tumour dissemination and the formation o f ascites. Recently, there have been several 
mouse models of ovarian cancer that rely on conditional expression of genes through 
Cre-recombinase mediated excision of specific sequences flanked by loxP sites 
containing these genes (Connolly 2009). This is accomplished by locally administering 
adenovirus that expresses Cre-recombinase to the mouse ovarian bursa. For example, 
one study developed LoxP-Stop-LoxP-A>as 0120 ' Pten loxP/Loxf miCe with conditional 
activation of Kras and conditional inactivation of Pten, which was the first genetic mouse 
model of endometrioid EOC; a cell line developed from these mice will be discussed later 
(Dinulescu, Ince et al. 2005). Another mouse model that develops tumours that are 
histologically similar to endometrioid EOC is the Pten LoxP/LoxF Ape LoxP/LoxP mouse model 
with conditional inactivation of the Pten and Ape genes (Wu, Hendrix-Lucas et al. 2007). 
As well, p53 and Rb are conditionally-inactivated in p53 LoxP/LoxF Rfr loxP/loxh mjce? and 
tumours that are formed in these mice resemble serous EOC (Flesken-Nikitin, Choi et al.
2003).
Ideally, other in vivo model systems need to be used in order to complement 
mouse EOC studies and address some of the limitations of the current xenograft and 
genetically-engineered mouse models. One such model that has rarely been used to study 
EOC, but that offers many unique advantages, is the chick chorioallantoic membrane 
(CAM) model system. I will discuss several characteristics of this model system as well 
as the few ovarian cancer studies that have utilized this system in order to highlight 
several of the unique advantages of this model that can be utilized to study EOC.
1.3.2 Chick chorioallantoic membrane
In the developing avian embryo, the chick CAM is a specialized tissue that 
functions as a lung for the embryo, as it is responsible for gas and nutrient exchange 
between the embryo and the surrounding atmosphere (Deryugina and Quigley 2008). 
Initially, the CAM is formed between days 5 and 6 of embryonic development due to the 
partial fusion of chorion and allantois. It is a very thin structure that usually less than 100 
pm in thickness once it is fully formed (Deryugina and Quigley 2008). Histologically, it 
consists of 3 main layers (Deryugina and Quigley 2008).The first layer is the ectoderm, 
which is usually attached to the shell membrane and is one or two epithelial cell layers in 
thickness. This layer eventually develops into the capillary plexus around day 10, which 
is a network of capillaries that connect arterial and venous blood vessel networks that 
contribute to a highly vascularized tissue. The middle layer is the mesoderm that also has 
many blood vessels, of which some are terminal capillaries that end immediately below 
the ectoderm. This layer also contains stromal components and collagen fibers. Finally, 
the third and innermost layer is the one-cell layer thick flat endoderm, which separates
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the rest of the CAM from the allantoic cavity. Between days 10-15, there are 2 types of 
inflammatory cells that can present themselves in the embryos (Deryugina and Quigley 
2008). The first group is the heterophils, which are the avian equivalent to mammalian 
neutrophils. The second group of inflammatory cells is the monocytes. Both of these 
inflammatory cells are sources of growth factors and pro-angiogenic MMPs, and 
therefore facilitate angiogenic responses.
With respect to cancer, the chick CAM has been used as an in vivo model to 
evaluate angiogenesis (Chim, Qin et al. 2011), primary tumour growth (Gao, Cao et al. 
2004), metastasis (Subauste, Kupriyanova et al. 2009), and to screen potential drugs 
(Shen, Wang et al. 2010). There are several advantages of using the chick CAM model 
system. For example, until day 11 or 12 o f embryonic development when the CAM has 
expanded to fully envelope the embryo, the CAM vasculature is undergoing maturation 
through the constant generation of new blood vessels (Deryugina and Quigley 2008). 
Immediately prior to this time between days 8 and 10, the central portion of the CAM is 
developed and is very responsive to proangiogenic or antiangiogenic stimuli. Therefore, 
the CAM is used as a model to test pro- or antiangiogenic compounds (Deryugina and 
Quigley 2008). Additionally, the lymphoid system of the CAM is not fully formed until 
the late stages of incubation, and is therefore relatively immunotolerant early in 
development (Deryugina and Quigley 2008). As a result, the CAM can accept most cell 
grafts without species-specific limitations, such as human tumour cells. Another benefit 
of the chick CAM is that growth of tumour xenografts on the surface of the chick CAM is 
very rapid (Figure 1.3), which is evidenced by the fact that visible tumours grow as early 
as 4-7 days after tumour cell inoculation. In fact, some tumour cell types under ideal
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Figure 1.3 Rapid growth of tumour xenografts in the chick CAM model system
(A) The highly vascularized chick CAM consists of three main layers. Epithelial ovarian 
cancer cells can be xenografted onto the surface o f the chick CAM, and (B) are 
inoculated at sites where large blood vessels at the surface intersect. Inoculating cells at 
these sites will increase the probability of successful tumour formation. (C) After 7 days,
1 x 106 MOSERM cells that had been seeded onto the CAM formed a tumour between 1 
and 2 mm in diameter. Scale bars: 2 mm.
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seeding density conditions can form tumours as large as 500-600 mg within 7 days after 
inoculation (Ossowski and Reich 1980). As well, not only can large tumours be seen at 
the primary site of inoculation, but micrometastases can also be formed by invasion of 
primary tumour cells into the stroma and intravasation into blood vessels during this time 
period (Deryugina and Quigley 2008). As a result, multiple steps of human cancer 
progression can be recapitulated in the chick CAM model system in a very short period 
of time relative to other in vivo model systems. Additionally, the CAM is a very simple 
and inexpensive system relative to other models, making it ideal for large-scale 
screenings and experiments (Staton, Reed et al. 2009). In addition to inoculations on the 
surface of the CAM, test compounds or drugs can be injected intravenously or intra- 
allantoically. This is beneficial due to the fact that limited excretions out of the CAM 
allows for the maintenance of compounds in the circulation for extended periods of time. 
Similarly, the easy accessibility and simplicity of the system also allows for repeated 
treatments over time to the CAM if required.
However, there are some limitations of using the CAM system, particularly with 
respect to angiogenesis. First of all, the CAM itself is well vascularized. Therefore can be 
difficult to distinguish new capillaries from pre-existing capillaries (Staton, Reed et al. 
2009). As well, irritation of the CAM during inoculations or injections can cause 
inflammatory responses which can induce angiogenesis on its own (Deryugina and 
Quigley 2008). The chick CAM has long been used as a common model system in 
developmental biology, but has not been as common in the field of cancer research which 
has largely focused on mouse models in large part due to the ability to genetically 
engineer these models (Hagedom, Javerzat et al. 2005). However, relatively new studies
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have highlighted techniques that may allow for genetic manipulation of the avian embryo 
(Pekarik, Bourikas et al. 2003).
There are two ways in which the chick CAM can be prepared in order to perform 
various assays, which are called the ‘in ovo’ and ‘ex ovo' methods. In the in ovo method, 
fertilized eggs are placed in a humidified chamber at 37°C and the embryos are allowed 
to partially develop (Ribatti, Vacca et al. 1996). Then, a small window can be cut in the 
eggshell so that the underlying CAM is exposed and accessible. After this, the window is 
often covered with cellophane tape until the desired assay is performed. In the ex ovo 
method, the embryo and extraembryonic membranes are transferred to a Petri dish in the 
early stages of development, typically on day 3 or 4 of development (Auerbach, Kubai et 
al. 1974). The dish is then incubated at 37°C in a humidified chamber until the desired 
assay is performed. Therefore, the CAM develops in the Petri dish as a flat membrane, 
and reaches the edges of the dish as it develops (Ribatti, Vacca et al. 1996). While both 
techniques are considered to be minimally invasive, they both have advantages and 
disadvantages associated with them. It is argued that the in ovo method requires less 
maintainence during development (Staton, Reed et al. 2009). Additionally, embryos can 
be maintained to later stages of development using this method. Due to the fact that the 
entire CAM can be seen with the ex ovo method as opposed to only being able to see a 
small portion of the CAM, multiple xenografts can be placed onto the surface of each 
CAM (Ribatti, Vacca et al. 1996). Although, there can be loss of embryos within the first 
3 days following their transfer to Petri dishes, survival rates after this point are very good 
and are comparable to the in ovo method (Auerbach, Kubai et al. 1974).
The chick CAM has been used to study many types of cancer such as colon 
cancer (Kim, Hur et al. 2011), gliomas (Auf, Jabouille et al. 2010), and pancreatic cancer 
(Laklai, Laval et al. 2009). There have also been some studies that have investigated 
aspects of ovarian cancer using the chick CAM system. For example, Kaempferol is a 
naturally occurring flavonoid that is found in many fruits and vegetables (Luo, Rankin et 
al. 2009). It was shown that when OVCAR3 human ovarian cancer cells were treated 
with Kaempferol, tumour growth of these cells was decreased as measured by tumour 
weight. Additionally, angiogenesis was decreased in these treated cells as measured using 
an angiogenesis onplant assay. A very similar study was done which tested the effect of 
Apigenin on angiogenesis by placing Matrigel onplants containing Apigenin with 
OVCAR3 cells onto the CAM (Fang, Zhou et al. 2007). Apigenin, which is also a 
naturally occurring flavonoid, showed anti-angiogenic properties as measured by the 
number of new blood vessels formed. Studies have shown that soluble LI adhesion 
molecule (sLl) protein is expressed at high levels in primary EOC tumour samples 
(Fogel, Gutwein et al. 2003), and this protein has also been detected at high levels in the 
ascites fluid of ovarian cancer patients (Gutwein, Stoeck et al. 2005). The effects of sLl 
on angiogenesis were then assessed by using the chick CAM angiogenesis onplant assay, 
and it was shown that sLl significantly increases angiogenesis on the CAM based on 
blood vessel density (Friedli, Fischer et al. 2009). Another study used malignant ascites 
fluid (MAF) that was isolated from ovarian cancer patients using paracentesis 
(Richardson, Gunawan et al. 2002). Although the MAF contained VEGF, it also 
contained angiostatin and other anti-angiogenic factors. It was found that application of 
MAF to the surface of the chick CAM inhibited capillary formation. Other studies have
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been used to test the effectiveness of newly synthesized compounds on angiogenesis on 
the chick CAM before being applied to other model systems. For example, a library of 
compounds that were designed to be angiogenic inhibitors were applied directly to the 
surface of the chick CAM, and two compounds were identified to significantly inhibit 
angiogenesis as measured by blood vessel density (Dings, Chen et al. 2006). These two 
compounds were then applied to an in vivo model in which M AI48 human ovarian 
carcinoma cells were injected into athymic nude mice with or without daily 
administration of the compounds. It was found that both compounds reduced tumour 
growth as measured by tumour volume and weight, and these treated tumours were 
confirmed to have decreased microvessel density. The authors of the study then 
suggested that their next steps would be to complete ongoing toxicity profiles in mice 
followed by initiating phase I clinical trials in humans. Overall, the chick CAM can be 
used as an effective model system to study multiple aspects of tumourigenesis in various 
types of cancer. These studies that have been described that use the chick CAM to study 
EOC provide evidence that this system can be effectively utilized for additional EOC 
experiments. Therefore, my studies will involve using this model system in order to 
further support its use as an effective tool to study EOC.
1.4 Objectives and experimental rationale
Based on previous data showing that upregulated BMP signaling decreased the 
ability of EOC tumour cells to metastasize to form secondary nodules upon injection into 
mice (Shepherd, Mujoomdar et al. 2010), I hypothesize that upregulated BMP signaling 
in the mouse EOC cell lines will decrease EOC tumour formation on the chick CAM by
decreasing the rate of proliferation, and by inhibiting the angiogenic potential of these 
cells. This hypothesis will be addressed by completing the following objectives:
A. Characterize proliferation, tumour formation, angiogenesis, and BMP signaling gene 
expression in MOSERM, MASC2, and 4306 mouse EOC cell lines in vitro and on the 
chick CAM
B. Assess role of altered BMP signaling on EOC tumourigenesis and angiogenesis
C. Assess applicability of the chick CAM as an alternative model system that can be used 
to study multiple aspects of EOC progression, specifically tumour formation and 
angiogenesis
One of the important aims of my research is to support the use of the chick CAM 
as an alternative model system that can be used to study multiple aspects of EOC 
metastasis. The MOSERM, MASC2, and 4306 mouse EOC cell lines have not been well 
characterized in the literature. Therefore, given that each of these cell lines formed in 
mice, I will determine whether these cells will also be able to form tumours in another 
model system by seeding them onto the chick CAM. I will then further characterize these 
three mouse EOC cell lines by investigating what mechanism(s) are responsible for the 
differences in tumourigenic potential that may be seen between the cell lines on the chick 
CAM.
BMP signaling has been implicated in multiple aspects of EOC tumourigenesis 
including EMT transition, cell adhesion, motility, and invasive potential in vitro 
(Shepherd and Nachtigal 2003; Moll, Millet et al. 2006; Theriault, Shepherd et al. 2007). 
It has also been implicated in limiting the ability of EOC cells to form secondary tumour 
nodules in vivo (Shepherd, Mujoomdar et al. 2010). Therefore, I will further characterize
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the MOSERM, MASC2, and 4306 cell lines by assessing their relative expression levels 
of 84 TGFp/BMP signaling-related genes compared to normal mouse EOC cells. 
Additionally, I will compare the relative BMP signaling expression levels of the mouse 
EOC cell lines with one another in order to determine if there are any expression patterns 
that will correlate with other tumourigenic properties that will be assessed.
Essential to gaining a better understanding of the complex roles that BMP 
signaling plays in EOC is to alter the expression and activity of this pathway in 
MOSERM, MASC2, and 4306 cells. One approach to accomplish this is to stably- 
transfect cells with ALK3QD, which is a constitutively-active type I BMP receptor. BMP 
signaling will also be altered in parental mouse EOC cell lines by administering short­
term treatment of BMP4, BMP antagonist noggin, or BMP receptor type I inhibitor LDN- 
193189. These methods will allow me us to assess the role of altered BMP signaling on 
tumour formation on the chick CAM, proliferation, cell survival, and angiogenesis using 
multiple strategies.
Angiogenesis will be assessed in the ALK3QD clones as well as in the initial 
characterization of angiogenic potential in the three parental mouse EOC cell lines by 
using an innovative chick CAM angiogenesis onplant assay. I will therefore have the 
opportunity to further develop the chick CAM as a model system that can be used to 






The MOSERM cell line (gift from Dr. Barbara Vanderhyden, University of 
Ottawa, Ottawa, ON) was derived from mouse ovarian surface epithelial cells isolated 
from transgenic mice expressing a temperature sensitive mutant of SV40 large T antigen 
(Yao, Li et al. 2006). These cells were subsequently transfected with plasmids to 
ectopically express the Ras and Myc oncogenes. The MASC2 ovarian cancer cell line 
(gift from Dr. Barbara Vanderhyden, University of Ottawa, Ottawa, ON) was derived 
from the ascites fluid of mice with metastatic ovarian tumours due to the conditional 
transgenic expression of SV40 large T antigen specifically in the OSE (Laviolette, 
Garson et al. 2010). The 4306 ovarian cancer cell line (gift from Dr. Daniela Dinulescu, 
Brigham and Women’s Hospital, Boston, MA) was derived from the ascites fluid of 
conditional transgenic mice with metastatic ovarian cancer. These mice express 
oncogenic mutant KrasGl2D in addition to having an inactivated Pten tumour suppressor 
gene specifically in the OSE (Dinulescu, Ince et al. 2005).
2.2 Cell culture
The MOSERM and MASC2 murine ovarian cancer cell lines were grown in 
Alpha Modification of Eagles’ Medium (AMEM -  Wisent, St. Bruno, QC, Canada) 
supplemented with 5% Fetal Bovine Serum (FBS -  Wisent). The 4306 murine ovarian
50
cancer cell line was grown in Dulbecco’s Modified Eagle’s Medium (DMEM -  Wisent) 
supplemented with 5% FBS. MOSERM, MASC2, and 4306 cells were grown in standard 
tissue culture-treated polystyrene plates (Sarstedt, Montreal, QC). Primary HUVECs (gift 
from Dr. John Lewis, London Regional Cancer Program, London, ON) were grown in 
Endothelial Cell Complete Growth Medium (EGM -  Lonza, Walkersville, MD) 
containing 2% FBS and supplemented with 0.4% Bovine Brain Extract (BBE -  Lonza). 
HUVECs were grown and maintained in Cell+ T175 flasks (Sarstedt). Cells were 
detached from tissue culture plates for passaging with 0.25% Trypsin/1%EDTA solution 
(Wisent), which would then be deactivated with media containing 5% FBS. Cells were 
maintained in humidified chambers at 37°C with 95% air and 5% CO2 .
2.3 Establishment of GFP and GFP-ALK3QD clones
MOSERM, MASC2, and 4306 GFP clones were previously created (work 
completed by Yudith Ramos-Valdes) using a murine stem cell virus (MSCV) retroviral 
vector. HEK293T cells were used as a packaging cell line, which were transfected using 
SuperFect® Transfection Reagent (Qiagen, Toronto, ON). At day 1, the SuperFect® 
Transfection Reagent was added to DMEM along with a MSCV Puro IRES GFP viral 
vector (MSCV PIG) containing GFP and the Puromycin resistance gene, v|/ packaging 
vector, and vesicular stomatitis virus glycoprotein (VSVG) plasmid. After 24 hours, 
media on the transfected plates was changed. At day 5, approximately lOOpL of virus 
containing media from the HEK293T transfected plates was added to 6cm plates with the 
cell lines of interest that were to be infected (MOSERM, MASC2, 4306). After 24 hours, 
media on these infected plates was changed. Finally, these cells were placed under
Puromycin (BioShop, Burlington, ON) selection pressure at a concentration of lpg/mL 
after which time 5 GFP-expressing clones from each of the parental cell lines 
(MOSERM, MASC2, 4306) were isolated and expanded (worked completed by Yudith 
Ramos-Valdes).
ALK3QD clones were created by transfecting MOSERM-GFP, MASC2-GFP, 
and 4306-GFP cells with a pcDNA 3.0 expression vector (Invitrogen, Carlsbad, CA) 
containing hemagglutinin (HA) -tagged hALK3QD. The ALK3QD (Q233D) BMP type I 
receptor contains a Q-to-D point mutation in its glycine/serine rich domain at amino acid 
233 (Hoodless, Haerry et al. 1996). As a result, this removes the requirement of 
transphosphorylation by BMPRII due to BMP ligand binding for the BMP type I receptor 
to be activated. GeneJuice® Transfection Reagent (Novagen, Mississauga, ON) was used 
in these transfections. Briefly, 15 pL GeneJuice® was added to 300pL of either AMEM 
(MOSERM GFP and MASC2 GFP cells) or DMEM (4306 cells) followed by the 
addition of 5 pg HA-tagged hALK3QD pcDNA 3.0 (0.45 pg/pL). This mixture was 
added to 60mm plates that were going to be transfected, which were then incubated for 
72 hours. After this time, cells were placed under G418 (Wisent) selection pressure at 
concentrations of 800 pg/mL for 10-14 days. After this time, 4 MOSERM, 2 MASC2, 
and 5 4306 GFP ALK3QD clones were isolated and expanded.
2.4 In vitro cell proliferation and survival assays
Cell proliferation was assessed either by cell counting using a haemocytometer, or 
by alamarBlue® (Invitrogen) proliferation assays. For cell counting, 5000 cells of each 
cell line were seeded onto 60 mm plates in 5 mL media, and were grown for up to 5 days.
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Each day, adherent cells were exposed to trypsin for all approximately 5 minutes, and 
following cell detachment, the trypsin was inactivated using FBS-containing media. To 
evaluate total cell number, trypsinized cells were counted using a haemocytometer by 
averaging 2 haemocytometer counts for each plate.
For alamarBlue® proliferation, 500 cells were seeded into the wells of 96-well 
plates, and were grown for up to 5 days in 200 pL of media. At each time point (days 0,
1, 2, 3, 4, 5) media was aspirated and replaced with 200 pL of a 1:20 ratio of 
alamarBlue®: media. The alamarBlue® treated 96-well plates were then incubated at 37°C 
for 4 hours. At this time, the reactions were measured fluorometrically using a Wallac 
1420 Multilabel Counter (Perkin Elmer Wallac, Gaithersburg, MD) with a fluorescence 
protocol. This protocol uses a fluorescence excitation wavelength of 570 nm, and 
fluorescence emission at 585 nm in order to quantify fluorescence units.
(K)Cell survival was measured using similar conditions as the alamarBlue 
proliferation assay, but with some modifications. For the MOSERM and MASC2 cell 
lines, 5000 cells were seeded into the wells of a 96-well plate. For the 4306 cell line, 
10000 cells were seeded into the wells of a 96-well plate. The cells were then grown for 
up to 5 days in 200 pL of serum-free media (0% FBS). At each time point (days 0, 1,2,
3, 4, 5), media was aspirated and replaced with 200 pL of a 1:20 ratio of alamarBlue®: 
serum-free media. Cell survival was then measured as described above using the Wallac 
1420 Multilabel Counter. Seeding densities are based on a preliminary 5 day serum- 
starving alamarBlue® experiment in which various quantities of cells (2000-10000 cells 
in 96-well plates) for each line were seeded in order to determine the minimum amount
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of cells that had to be seeded in order to be able to achieve a quantifiable fluorescence 
signal after 5 days.
2.5 RNA isolation and gene expression profiling
RNA isolation from cells grown in monolayer was completed by using an RNeasy 
Mini Kit (Qiagen) as per manufacturer’s instructions. The isolated RNA was then treated 
using an Amplification Grade DNase I kit (Sigma-Aldrich, Oakville, ON) in order to 
remove contaminating DNA as per manufacturer’s instructions. The quality and quantity 
of the isolated RNA was determined using a Nano Drop 1000 Spectrophotometer 
(NanoDrop Products, Wilmington, DE).
Gene expression profiles for the MOSERM, MASC2, and 4306 cell lines were 
assessed by using a TGFJ3/BMP Signaling Pathway RT2 Profiler PCR Array System 
(SABiosciences # PAMM-035, Frederick, MD). This array uses 96-well plates that 
contain optimized primers in each well for genes of interest that are involved in the 
TGFp/BMP signaling pathway. The array also contains wells for several housekeeping 
genes, as well as control wells for PCR performance, RNA quality, and genomic DNA 
contamination. Briefly, 1 pg DNase-treated RNA was used for first strand cDNA 
synthesis that was completed using an RT2 First Strand Kit (SABiosciences) as per 
manufacturer’s instructions. This newly-synthesized cDNA in a volume of 102pL was 
mixed with RT2 S YBR® Green/Rox1M qPCR Master Mix (SABiosciences) as per 
manufacturer’s instructions that contained all of the buffers and reagents that are required 
for real-time PCR (real-time PCR buffer, nucleotides, high-performance HotStart DNA 
Taq polymerase, ROX® reference dye). Then, 25 pL of the master mix/cDNA mixture
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was aliquoted in each of the wells of the 96 well-plates, and plates were run using a 
Strategene Mx3000P QPCR machine (Agilent Technologies, Cedar Creek, TX). Data 
analysis of the results was quantified using a PCR Array Data Analysis Web Portal for 
Excel (SABiosciences).
2.6 Western blotting
Total cellular protein was isolated by first scraping cells from their cell culture 
plates, and then washing them with cold Dulbecco’s Phosphate-Buffered Saline (PBS) 
(Wisent). These cells were pelleted by centrifugation (5 minutes at 2000 x g), and were 
then dissolved in lysis buffer (50mM HEPES pH 7.4, 150mM NaCl, 10% glycerol, 
1.5mM MgCb, ImM EGTA, 10 mM sodium pyrophosphate, ImM sodium 
orthovanadate, lOmM NaF, ImM PMSF, 0.1% SDS, 1% sodium deoxycholate, 1%
Triton X-100, and IX protease inhibitor cocktail (Roche, Mississauga, ON)) for 20 
minutes, at which time total cellular protein was clarified by centrifugation (20 minutes at 
14000 xg).
The protein concentration of each lysate was determined by Bradford analysis as 
described previously (Bradford 1976), with some modifications. Briefly, a standard curve 
was generated using increasing concentrations of Bovine Serum Albumin (BSA) (New 
England Biolabs, Pickering, ON) by using Protein Assay Dye Reagent Concentrate (Bio- 
Rad Laboratories, Mississauga, ON). The colourimetric assay was quantified using a 
Model 3550 Microplate Reader (Bio-Rad Laboratories). Protein samples were then 
diluted by between 1:100 and 1:1000 in PBS, and 200pL of diluted protein was added to 
wells in a 96-well plate. lOOpL of Protein Assay Dye Reagent that was diluted 2:1 with
54
PBS was added to each well, and values were quantified using the Model 3550 
Microplate Reader. Finally, protein concentration was determined based on interpolation 
using the standard curve.
Protein extracts (50-90 pg) were resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) using 8% or 12% gels. These proteins 
were transferred to a polyvinylidene difluoride membrane (PVDF -  Roche), and were 
subsequently blocked with 5% skim milk in Tris-buffered saline and Tween 20 (TBST -  
lOmM Tris-HCl pH 8.0, 150mM NaCl, 0.1% Tween 20) for at least one hour at room 
temperature. Membranes were washed in TBST and incubated overnight at 4°C in TBST 
in 5% skim milk with 0.02% NaN3 and appropriate concentrations of primary antibodies 
(actin, ID1, ID3, phospho-Smad 1/5/8, Smadl, HA high affinity -  1/1000). After this, the 
membranes were incubated in anti-rabbit horseradish peroxidase (HRP)-linked secondary 
antibody (1/10,000 - GE Healthcare, Piscataway, NJ) for one hour at room temperature. 
Membranes incubated with anti-HA high affinity primary antibody were incubated in 
goat anti-rat HRP-linked secondary antibody (1/25,000 -  Thermo Fisher Scientific, 
Toronto, ON). Immunoreactive bands were visualized by incubating the membranes for 
five minutes with chemiluminescence detection reagent (ECL Plus -  GE Healthcare), 
exposing them to Hyperfilm™ ECL high performance chemiluminescence film (GE 
Healthcare), and developing them using a Kodak M35A X-OMAT Processor (Kodak 
Graphic Communications Company, Toronto, ON).
In some instances, blots were stripped to reprobe with different primary 
antibodies. Briefly, membranes were incubated with stripping buffer (2% SDS, lOOmM 
P-mercaptoethanol, 62.5mM Tris-HCl pH 6.8) for approximately 45 minutes at 70°C.
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The membranes were washed several times in TBST for at least 40 minutes. After this, 
membranes were reprobed beginning with blocking the membranes with 5% skim milk in 
TBST for at least one hour at room temperature as described above.
2.7 Antibodies and other reagents
Antibodies against total Smadl (# 9517) and phospho-Smad 1/5/8 (# 9511) were 
purchased from Cell Signaling Technologies (Danvers, MA). The antibodies against ID1 
(# BCH-1/195-14) and ID3 (# BCH-4/6-1) were purchased from BioCheck Inc. (Foster 
City, CA). Anti-actin antibody (# A2066) was purchased from Sigma-Aldrich. Anti-HA 
high affinity antibody (# 11 867 423 001) was purchased from Roche. LDN-193189 BMP 
type I receptor inhibitor was purchased from Axon Medchem BV (Groningen, The 
Netherlands). Recombinant human Noggin and BMP4 were both purchased from R&D 
Systems #6057-NG-025 and 314-BP-010, Burlington, ON). LDN-193189, Noggin, and 
BMP4 were reconstituted as per product specifications.
2.8 Chick CAM tumour imaging and growth assay
Tumour growth assays on the chick CAM were performed similarly to other 
studies (Mitchell, Pobre et al. 2010). Fertilized White Longhorn chicken eggs were 
purchased from McKinley’s Hatchery (St. Mary’s, Ontario), and incubated in a rotary 
incubator at 38°C and 80% humidity. At day 4 of development, eggshells were removed 
and the embryos were carefully placed into weigh boats. Embryos were covered with lids 
and placed in a humidified stationary air incubator at 38°C and 80% humidity. At day 10 
of development, the CAM was gently abraded with sterile filter paper that was
approximately 7 mm in diameter. After 10 minutes, the filter paper was gently removed 
using jeweler’s forceps, and 25uL of cells (1,000,000 cells per 25uL PBS) were 
inoculated onto the surface of the CAM at the abraded site. Inoculation sites were chosen 
where large blood vessels intersected on the surface of the CAM, and that were also 
approximately an equal distance between the embryo and the edge of the weigh boat. The 
embryos were returned to the humidified stationary air incubator for the remainder of the 
experiment. After 7 days of incubation (i.e. at day 17 of development), images of tumour 
nodules were captured using PS Remote (Breeze Systems Ltd, Camberly, UK) and Paint 
Shop Pro 9 (Jasc Software, Ottawa, ON) with a StereoLumar.V12 fluorescence dissection 
microscope (Carl Zeiss, Toronto, ON) mated to a Hamamatsu ORCA-ER camera (Digital 
Imaging Systems Ltd, Buckinghamshire, UK). After imaging, tumours were excised and 
placed in Formalde-Fresh Solution (Thermo Fisher Scientific) overnight, and were then 
weighed using a Mettler AE240 digital semi-micro analytical balance (Mettler-Toledo 
Inc, Columbus, OH).
2.9 In Vitro angiogenesis assay
In vitro angiogenesis assays were performed as described previously (Kubota, 
Kleinman et al. 1988), with some modifications. Matrigel1M Basement Membrane Matrix 
(BD Biosciences, Mississauga, ON) which is a solubilized basement membrane extracted 
from Engel-Holm-Swarm (EHS) sarcomas, was diluted 1:2 with chilled EGM. This 
diluted Matrigel (60pL) was added to wells of a 96-well culture plate, and incubated at 
37°C for 1-2 hours to allow for polymerization. HUVECs were plated onto the layer of 
gelled Matrigel at a concentration of 10,000 cells/50pL EGM, and were co-cultured with
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50pL of mouse epithelial ovarian cancer cells (5000 cells/50pL media) in serum-free 
media. The plates were incubated at 37°C in 5% CC>2/95% air. After 3-6 hours, each well 
was photographed with an Olympus 1X70 inverted microscope using Image-Pro Plus 6.2 
(Media Cybernetics Inc., Bethesda, MD). Endothelial tube formation was quantified in 
each well by counting the number of branch points in 6-12 random fields of view at 100X 
magnification.
2.10 Chick CAM angiogenesis assay
Angiogenesis assays were performed as described previously (Seandel, Noack- 
Kunnmann et al. 2001), with some modifications. Briefly, high concentration rat-tail type 
I collagen (BD Biosciences) in autoclaved H2 O was neutralized with 10X PBS and 0.1N 
NaOH at a ratio of 8:1:1. The volumes of rat-tail type I collagen/autoclaved water varied 
to attain a final concentration of neutralized collagen at 2.5 mg/mL. Hepes solution 
(Sigma Aldrich) was added at a final concentration of 20mM to ensure a stable pH of 7.4. 
The pH of the final neutralized collagen solution was tested and additional 0.1 N NaOH 
was added if necessary. Two parts of neutralized collagen solution were combined with 
one part sterile IX PBS containing BSA (final concentration 1 mg/mL) as a carrier 
protein. Finally, cells of interest were incorporated into the collagen at a concentration of 
4 x 107 cells per mL.
Thirty microlitres of the final collagen/cell solution were pipetted onto 2 layers of 
sterile nylon mesh grids (Innovascreen, Halifax, NS). The mesh, which was cut and 
autoclaved beforehand, was prepared by placing the upper mesh (2mm x 2mm) onto the 
lower mesh (3mm x 3mm) at a 45° angle. For each experimental group, 40 collagen/mesh
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onplants were laid onto Parafilm (Pechiney Plastic Packaging Company, Cleveland, OH) 
in 100 x 100 mm Petri dishes, and placed at 37°C for 3 hrs to allow for collagen 
polymerization into fibrils. Jeweler’s forceps were used to place four onplants onto each 
CAM of 9-day-old chick embryos. The onplant-bearing embryos were incubated for an 
additional 3 days, at which time onplant vascularization was quantified. Newly formed 
vessels were identified by analyzing the upper plane of the onplant with a dissecting 
microscope. The angiogenic index of the onplants was determined as the percentage of 
mesh grids that contained newly formed blood vessels out of the total number of grids in 
the upper mesh. Images were captured using Volocity (Improvision Inc., UK) with a 
StereoLumar.V12 fluorescence dissection microscope mated to a Hamamatsu ORCA-ER 
camera.
2.11 Statistical Analyses
Data are expressed in figures as the mean ± standard error of the mean (SEM). 
When comparing an experimental sample with its matched control, a two-tailed unpaired 
Student’s t-test was used. To compare the means among more than two samples, a one­
way analysis of variance was used followed by Tukey’s post hoc analysis. Differences 
with p  values < 0.05 are considered to be statistically significant. These statistical 
analyses were performed using GraphPad Prism version 3.0 software (GraphPad 




3.1 MOSERM and 4306 mouse ovarian cancer cell lines form tumours on the
chick chorioallantoic membrane (CAM)
The MOSERM, MASC2, and 4306 mouse ovarian cancer cell lines have not been 
well characterized either in vitro or in vivo in the literature. Given that each of these cell 
lines are able to form tumours in mice, I sought to determine the tumourigenic potential 
of each cell line in another model system by seeding them onto the chick CAM. The 
GFP-expressing clones that our lab has previously developed (work by Yudith Ramos- 
Valdes) were used for this experiment so that cells could be visualized by fluorescence 
microscopy even if macroscopic tumours were not formed, and to confirm that nodules 
that were formed were indeed composed of ovarian cancer cells. For each cell line, 1 x 
106 cells in 25pL were seeded onto the surface of the CAM. After one week, tumour 
formation was assessed. MOSERM and 4306 cells form macroscopic tumour nodules on 
the chick CAM that and are consistently larger than 1 mm in diameter (Figure 3.1 A). In 
fact, MOSERM tumours are visibly larger than the 4306 tumours. Since MASC2-GFP 
cells that were seeded onto the CAM did not form visible tumour nodules, fluorescence 
images were taken every day after the initial seeding to determine if these cells were 
present and able to survive on the CAM (data not shown). Although these cells were 
visible under fluorescence on the CAM up to approximately four days after seeding, they 
were no longer detectable on the CAM by day 7.
61
Figure 3.1 MOSERM and 4306 cells form tumours on the chick CAM.
Approximately 1 x 106 cells were seeded onto the surface of each chick CAM at 
embryonic day 11. (A) Brightfield and fluorescent images of the xenograft locations were 
taken 7 days after the initial seeding at 20X magnification. (B) The tumours were then 
excised from the surface of the CAM, placed in formalin overnight, and weighed. Error 
bars represent the standard error of the mean for tumour weight from at least 6 excised 
tumours per group. Asterisks indicate statistically significant differences between 
treatments (**p = 0.0087). Scale bars: 2 mm.
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In order to quantify differences in the size of the tumours formed on the chick 
CAM between MOSERM and 4306 cells, the tumours were excised and weighed. 
MOSERM cells consistently formed tumours with an average weight of 9.1 ± 1,9mg that 
were significantly larger than tumours formed from 4306 cells (p = 0.0019), which had an 
average weight of 3.3 ± 0.4mg (Figure 3 .IB).
3.2 Tumour forming ability on chick CAM does not correlate with in vitro
proliferation
To evaluate whether differences in the rate of proliferation between each cell line 
were correlated with their abilities to form tumours on the chick CAM, in vitro 
proliferation studies were completed over five days. Among the three mouse ovarian 
cancer cell lines, MOSERM cells exhibited the highest rate of proliferation. These cells 
grew from an initial seeding density of 5000 cells to 11.5 x 106 cells within the 5 day 
period of this assay (Figure 3.2A), and had a peak doubling time of 9.8 hours (Figure 
3.2B). MOSERM cells grew significantly more rapidly than both the MASC2 and 4306 
cell lines (p < 0.001). Interestingly, MASC2 cells proliferate with a peak doubling time of
11.4 hours, which represented growth from 5000 to 3.5 x 106 cells within 5 days. This 
level of proliferation for MASC2 cells is significantly greater than 4306 cells (p < 0.05), 
which have a peak doubling time of 12.8 hours that represents growth from 5000 to 1.5 x 
106 cells in 5 days.
64
Figure 3.2 Differences in the rate of proliferation of mouse EOC cell lines grown 
in vitro.
For each cell line, 5000 cells were seeded onto 60 mm plates and were grown for up to 5 
days. At each time point, cells were trypsinized and counted. (A) Values represent the 
average number of cells between 3 replicates, and 2 haemocytometer counts were 
performed for each replicate. Bars represent the standard error of the mean for each group 
at each time point. (B) The peak doubling time for each cell line was calculated in hours 
by using the formula To = l/[ln(Nt/N0)/t](ln2) where Nt is the number of cells after the 
desired time interval (5 days) in the exponential growth phase, N0 is the number of 















3.3 In vitro angiogenesis correlates with mouse EOC cell line tumour-forming 
ability on the chick CAM
Since the rate of proliferation of each cell line does not correlate with their 
relative abilities to form tumours on the chick CAM, we sought to investigate 
angiogenesis as a potential mechanism to define these tumour formation differences 
among cell lines. To accomplish this, HUVECs were co-cultured with each cell line in 
low serum-containing media (1% FBS) on a layer a Matrigel in 96-well plates. After 6 
hours, multiple images of each well at 100X magnification were taken, and representative 
images of wells with HUVEC branching in the presence of AMEM treatment (Figure 
3.3A) or MOSERM cells (Figure 3.3B) are shown. MOSERM cells significantly 
enhanced the ability of HUVECs to form branches (16.6 ± 0.5 branches per field of view) 
relative to AMEM alone (12.4 ± 0.3 branches per field of view; p  = 0.0016; Figure 3.3C). 
Co-culture of HUVECs with 4306 cells also significantly enhanced HUVEC branching 
(10.7 ± 0.2 branches per field of view) compared to DMEM alone (8.0 ± 1.0 branches per 
field of view; p  -  0.0191). In contrast, treatment of HUVECs with MASC2 cells did not 
significantly affect the rate of branching (8.1 ± 1.0 branches per field of view) when 
compared to AMEM alone (7.8 ± 0.7 branches per field of view).
3.4 In vivo angiogenic potential of mouse EOC cells assessed using the chick
CAM
The chick CAM has been previously been used as an in vivo model system to 
assess angiogenesis. In order to determine if the abilities of MOSERM and 4306 cell 
lines to induce angiogenesis in vitro can also be detected in vivo, chick CAM
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Figure 3.3 Angiogenesis as a potential mechanism defining differences in mouse 
EOC tumour formation on the chick CAM.
1 x 104 human umbilical vein endothelial cells (HUVECs) were plated onto Matrigel and 
co-incubated with 5000 MOSERM cells, MASC2 cells, or 4306 cells in low serum- 
containing media (1% FBS) in 96 well plates. After 3-6 hours, angiogenesis was 
quantified. Angiogenesis is measured by counting the number of branches formed by 
HUVECs per field of view. Representative images of branches within a field of view in a 
96-well plate at 100X magnification are shown for AMEM control (A) and MOSERM 
cells (B). HUVEC branches are indicated by black arrows. The image for AMEM 
treatment contains 13 branches, while the image for MOSERM treatment contains 16 
branches. (C) Branch counts for each cell line are represented by grey bars, while branch 
counts for their respective serum-free media treatments are represented by black bars. 
Error bars represent standard error of the mean for the average number of branches based 
on at least 4 wells per group. Pairwise comparisons were made within each pair of 
treatments, and asterisks indicate statistically significant differences within each pair (*p 















angiogenesis assays were performed as described previously (Seandel, Noack-Kunnmann 
et al. 2001). Angiogenesis was quantified by expressing the number of grids that are 
positive for blood vessel sprouting as a percentage of total grids in each mesh. 
Representative images of blood vessel sprouting are shown for PBS control (Figure 3.4A) 
and MOSERM cell (Figure 3.4B) groups. Quantification of the PBS control group 
indicated a baseline level of new blood vessel sprouting over the 3-day period of the 
experiment, which was approximately 7.8 ± 0.5% of the total grid area (Figure 3.4C). 
Collagen onplants containing MASC2 cells induced angiogenesis in an average of 11.4 ±
1.7% of grid boxes. However, this difference in blood vessel sprouting is not statistically 
significant between the PBS and MASC2 groups. MOSERM collagen onplants showed 
angiogenic sprouting in 18.3 ± 2.5% of grid boxes, and 4306 onplants exhibited sprouting 
in 20.9 ± 1.3% of grid boxes. These enhanced levels of blood vessel sprouting are 
significantly greater in both the MOSERM (p < 0.05) and 4306 (p < 0.01) onplants 
relative to the PBS treatment group, as well as when compared to the MASC2 treatment 
group (p < 0.05). There was no significant difference in the degree of sprouting between 
the MOSERM and 4306 treatment groups.
3.5 Inverse correlation of mouse EOC cell line BMP4 signaling gene expression
and tumour formation on the chick CAM
BMP signaling has been implicated in the progression of ovarian cancer in 
numerous studies (Shepherd and Nachtigal 2003; Moll, Millet et al. 2006; Theriault, 
Shepherd et al. 2007; Shepherd, Theriault et al. 2008; Pils, Wittinger et al. 2010; 
Shepherd, Mujoomdar et al. 2010). Previously, 4306 cells have been shown to possess an 
intact Mullerian Inhibiting Substance (MIS) signal transduction pathway based on ALK2,
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Figure 3.4 Differences in angiogenic potential between mouse EOC cell lines are 
revealed on the chick CAM.
1 x 105 MOSERM, MASC2, or 4306 cells were embedded in collagen, which was then 
inserted between two mesh grids and placed on the surface of the chick CAM. After 3 
days, angiogenesis was quantified. The degree of new blood vessel sprouting was 
measured by counting the number of grid boxes within each mesh that were positive for 
blood vessel sprouting. Representative images with blood vessel sprouting for PBS 
control (A) and MOSERM cells (B) are shown. Examples of grid boxes that are positive 
for new blood vessel sprouting are indicated by black arrows. The PBS mesh grid 
contains 3 of 47 boxes that are positive for blood vessel sprouting (6.4%), while the 
MOSERM mesh grid contains 6 of 41 boxes that are positive for blood vessel sprouting 
(17.1%). Note that a positive grid is determined if blood vessel sprouting is present, 
regardless of how many sprouts are within that grid box. (C) The percentage of grids that 
were positive for angiogenic sprouting is represented for each treatment group. Error bars 
represent standard error of the mean for the average percentage of positive grids based on 
at least 7 mesh grids per group. Different letters represent statistically significant 
differences among groups (p < 0.05).
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ALK3, MISRII, and Smadl/5/8 mRNA expression (Szotek, Pieretti-Vanmarcke et al. 
2006). However, other aspects of TGFp/BMP signaling have never been assessed in these 
cells, and TGFp/BMP signaling has never been evaluated in MOSERM or MASC2 cells. 
Therefore, we sought to compare the BMP signaling expression profiles of these mouse 
ovarian cancer cell lines, and then investigated whether there were correlations between 
the BMP expression levels and the relative abilities of these cell lines to form tumours on 
the chick CAM or to induce angiogenesis. The gene expression profiles for the 
MOSERM, MASC2, and 4306 cell lines were assessed using a TGFp/BMP Signaling 
Pathway RT Profiler PCR Array System. As well, the gene expression profile of 
normal mouse OSE (isolated by Dr. Trevor Shepherd) was also assessed in order to 
provide an additional comparison to the three mouse ovarian cancer cell lines. In addition 
to the normal mouse OSE cells, the MOSERM, MASC2, and 4306 cell lines all have 
measurable, but distinct mRNA expression levels for the components required for BMP4 
signaling (BMP4 ligand, BMP receptors, receptor Smads, co-Smad4, BMP responsive 
target genes; Figure 3.5). BMP4 mRNA is expressed in MOSERM cells at a level of 8.3 
± 0.5% relative to the expression levels o f a panel of control genes, which was not 
significantly different than BMP4 expression in 4306 cells of 5.1 ± 1.0%. In mouse OSE 
cells, BMP4 is expressed at higher levels of 11.0 ± 0.2% when compared to 4306 (p < 
0.01), but not to MOSERM cells. Interestingly, BMP4 is expressed at 19 ± 0.9% in 
MASC2 cells, which is significantly higher than MOSERM, 4306, and OSE cells (p < 
0.001). One of the last steps in the BMP4 signaling pathway is the upregulation of target 
gene expression, such as the Ids. Idl mRNA is expressed in MOSERM cells at a level of
Figure 3.5 Expression of BMP pathway signaling components among mouse 
EOC cell lines and normal mouse OSE cells.
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TGFp/BMP signaling was assessed using a SABiosciences RT2 Profiler1 M PCR Array. 
Expression of mRNA for each group represents the average of arrays that were 
completed in duplicate, with error bars representing the standard error of the mean. The 
expression levels of each gene of interest for MOSERM, MASC2, 4306 and normal 
mouse OSE cells were normalized to the average expression level of a panel of five 
housekeeping genes (glucuronidase-beta (Gusb), hypoxanthine guanine phosphoribosyl 
transferase 1 (Hprtl), heat shock protein 90kDa alpha cystolic-class B member 1 
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9.5 ± 0.7%, at 11.1 ± 0.6% in 4306 cells, and 8.9 ± 0.8% in mouse OSE, with none of 
these groups having significantly different expression levels from one another. However, 
Idl in MASC2 cells is expressed at a level of 24.4 ± 0.1% relative to the expression 
levels of housekeeping genes, and is expressed at significantly higher levels compared to 
MOSERM, 4306, and OSE cells (p < 0.001). Similar to Idl, Id2 is not expressed at 
statistically different levels between MOSERM and 4306 cells, which express Id2 mRNA 
at levels of 9.6 ± 2.1% and 12.2 ± 0.4%, respectively. However, MASC2 cells express 
Id2 at a level of 24.6 ± 0.1%, and mouse OSE cells express Id2 at 26.9 ± 0.5%. These 
expression levels in MASC2 cells for Id2 are significantly greater than those for 
MOSERM or 4306 cells (p < 0.001). Other components of the BMP4 signaling pathway 
that were assessed (ALK3, BMPR2, Smadl, Smad4, Smad5) did not have statistically 
significant differences among cell lines or normal mouse OSE.
3.6 Ectopic stable expression of constitutively-active ALK3QD receptor in mouse
EOC cells
MOSERM-GFP, MASC2-GFP, and 4306-GFP cells were all stably transfected to 
express the constitutively active type I BMP receptor, ALK3QD (Hoodless, Haerry et al. 
1996). This ALK3QD is also HA-tagged so that successful transfections can be 
visualized by western blot. We originally screened 38 MOSERM clones, 12 MASC2 
clones, and 14 4306 clones. From these screens, two independent clones for each of the 
three cell lines were expanded that were positive for ALK3QD-HA expression (Figure 
3.6). The majority of these clones (MOSERM ALK3QD clones 1 and 2, MASC2 
ALK3QD clones 1 and 2, 4306 clone 1) exhibited a relatively low level of ALK3QD
Figure 3.6 Changes in BMP signaling as a result of transfection of mouse EOC 
cell lines with ALK3QD.
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Transfected ALK3QD clones are divided into two groups based on their BMP signaling 
expression levels compared to parental cells. (A) One group of transfected clones exhibits 
increased downstream BMP signaling relative to parental cells, while the other group (B) 
exhibits decreased BMP signaling compared to parental cells. (Top panel of A and B) 
Successful transfections of mouse EOC cell lines with HA-tagged ALK3QD was 
assessed with anti-HA high affinity. Western blotting was performed by using 90pg of 
total cellular protein, and equal loading was assessed with anti-actin. (Bottom panel of A 
and B) The effect of ALK3QD transfections on downstream BMP signaling was assessed 
using anti-phospho-smad 1/5/8, anti-ID 1, and anti-ID3. Western blotting was performed 
with 50pg of total cellular protein, and equal loading was assessed with anti-Smadl and 
anti-actin. BMP signaling was considered to be upregulated or downregulated based on a 
change in phospho-Smad 1/5/8 protein expression, as well as a change in at least one of 























expression as measured by western blot (top panel of Figure 3.6A and 3.6B), but 4306 
clone 2 exhibited much stronger ALK3QD expression compared to the other clones. 
Therefore, we were especially interested to investigate whether this strong signal would 
have unique functional consequences. The six clones are divided into two groups based 
on the effects of ALK3QD expression on downstream BMP signaling. These groups are 
differentiated based on whether downstream BMP signaling in the clones is upregulated 
or downregulated relative to parental cells. BMP signaling was considered to be 
upregulated or downregulated based on a change in phospho-Smad 1/5/8 protein 
expression, as well as a change in at least one of either Idl or Id3 protein expression. 
Clones with increased BMP signaling relative to parental cells are denoted by a (+) sign, 
while clones with decreased BMP signaling are denoted by a (-) sign.
The first group contains MOSERM ALK3QD clones 1 (+) and 2 (+), and 4306 
ALK3QD clone 2 (+) (Figure 3.6A). One of the first steps in the BMP signaling pathway 
is the phosphorylation of R-Smads, and we therefore assessed phospho-Smad 1/5/8 
protein expression compared to total Smad levels. The MOSERM clones in the first 
group exhibit an increase in phospho-Smad 1/5/8 expression relative to parental cells, 
although these clones also exhibit an increase in total Smad 1/5 (bottom panel of Figure 
3.6A). 4306 ALK3QD clone 2 (+) cells display a more pronounced increase in phospho- 
Smad 1/5/8 expression compared to 4306 parental cells, and do not have any noticeable 
changes in total Smadl/5 levels. In addition to phospho-Smadl/5/8, Idl and Id3 target 
gene protein expression were also assessed. Both of these proteins are expressed at higher 
levels in ALK3QD (+) clones in this first group when compared to parental cells,
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although changes in Idl and Id3 protein expression are more pronounced in the 
MOSERM ALK3QD (+) clones than in the 4306 ALK3QD (+) clone.
The second group of clones includes MASC2 ALK3QD clones 1 (-) and 2 (-), and 
4306 clone 1 (-) (Figure 3.6B). Both MASC2 ALK3QD clone 1 (-) and 4306 ALK3QD 
clone 2 (-) display a decrease in phospho-Smad 1/5/8 expression compared to parental 
cells, while MASC2 ALK3QD clone 2 (-) cells display a less apparent decrease in the 
expression of this protein (bottom panel Figure 6B). Additionally, total Smadl/5 
expression does not change between any of the clones and their respective parental cell 
lines. With respect to the Id proteins, Idl expression decreases in all three clones relative 
to parental cells. However, Id3 protein expression does not change among the clones and 
their parental cells.
3.7 Inverse correlation between BMP signaling expression levels in ALK3QD 
clones and ability to form tumours on the chick CAM
For each ALK3QD clone, 1 x 106 cells were inoculated onto the surface of the 
chick CAM, and were then incubated for one week at which time tumour formation was 
assessed. In addition to the ALK3QD clones, parental cells were also inoculated onto the 
chick CAM. Upon brightfield and fluorescence imaging of tumours formed on the CAM 
from these clones, MOSERM ALK3QD clone 1 (+) and clone 2 (+) are visibly smaller 
than tumours formed by the MOSERM parental cell line (Figure 3.7A). Similarly, 4306 
ALK3QD clone 2 (+) derived tumours are visibly smaller than those formed by parental 
4306 cells. Conversely, tumours that were formed by 4306 ALK3QD clone 1 (-) cells 
were visibly larger than those formed by parental 4306 cells. Although MASC2, MASC2
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Figure 3.7 Differences in size of tumours formed on the chick CAM among 
ALK3QD stably-transfected mouse EOC cell line clones.
Approximately 1 x 106 cells were seeded onto the surface of the CAM for each ALK3QD 
clone and their respective parental cell lines. (A) Brightfield and fluorescence images 
were taken of the cell xenograft locations at 20X magnification 7 days after the initial 
seeding. MOSERM (B) and 4306 (C) tumours were then excised from the surface of the 
chick CAM, fixed in formalin overnight, and weighed. Error bars represent the standard 
error of the mean o f tumour weights from at least 5 excised tumours per group. Different 
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ALK3QD clone 1 (-) and clone 2 (-) cells were also inoculated onto the surface of the 
CAM, they did not form visible tumours (data not shown). These qualitative observations 
of differences in tumour size were subsequently quantified by measuring tumour weight, 
which was accomplished by excising tumours after imaging, placing in formalin 
overnight and then weighing them. Tumours that were formed from MOSERM parental 
cells weighed approximately 8.3 ± 0.8mg, which had a significantly greater mass than 
both the MOSERM ALK3QD clone 1 (+) (p < 0.001) and clone 2 (+) (p < 0.01) chick 
CAM tumours (Figure 3.7B). The tumours formed by these clones weighed 
approximately 5.2 ± 0.3mg and 4.4 ± 0.7mg respectively, and their masses were not 
significantly different from one another. With respect to 4306 ALK3QD clones, the 
average weight of 4306 ALK3QD clone 2 (+) tumours was 1.7 ± 0.4mg compared to 
4306 parental cell derived tumours that were approximately 3.3 ± 0.4mg (Figure 3.7C). 
Although this indicates a trend towards decreased tumour mass in 4306 ALK3QD clone 2 
(+) relative to 4306 parental cells, this difference is not statistically significant. 
Conversely, 4306 ALK3QD clone 1 (-) cells form tumours that weigh approximately 10.7 
± 0.7mg, and have a significantly greater mass than 4306 parental cells (p < 0.001).
3.8 Changes in BMP signaling due to ALK3QD expression do not affect cell
proliferation in vitro
In order to determine which mechanism(s) might be contributing to the 
differences that are seen between ALK3QD clones and parental cells with respect to their 
abilities to form tumours on the chick CAM, we decided to first investigate cell 
proliferation as a potential mechanism. This was accomplished by completing
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alamarBlue® assays in vitro in full serum over a period of five days, and proliferation was 
quantified fluorometrically at days 0, 1,2, 3, and 5 for all mouse EOC cell lines and their 
respective ALK3QD clones. By day 5, the fluorimetric counts for MOSERM, MOSERM 
ALK3QD clone 1 (+), and MOSERM ALK3QD clone 2 (+) were not significantly 
different from one another (Figure 3.8A). As well, there were no significant differences 
in proliferation between MASC2 parental cells and MASC2 ALK3QD clones (Figure 
3.8B). Finally, neither 4306 ALK3QD clone displayed statistically significant differences 
in proliferation relative to 4306 parental cells (Figure 3.8C).
3.9 Inverse correlation between level of BMP signaling in mouse EOC ALK3QD
clones and degree of blood vessel sprouting on the chick CAM
Since altered BMP signaling does not correlate with in vitro cell proliferation in 
mouse EOC cell lines, I next sought to determine whether angiogenesis might be a 
potential mechanism contributing to the differences that are seen among ALK3QD clones 
and parental cells with respect to their abilities to form tumours on the chick CAM. 
Angiogenesis was assessed on the chick CAM using the collagen onplant assay as 
previously described, and angiogenesis was quantified by expressing the number of grids 
that are positive for blood vessel sprouting as a percentage of total grids in each mesh. 
Collagen onplants containing MOSERM cells contributed to new blood vessel sprouting 
in approximately 20.1 ± 2.0% of grid boxes (Figure 3.9A). This induction of 
angiogenesis was significantly greater than the PBS control group (11.4 ± 1.3% of grid 
boxes; p  < 0.01), the MOSERM ALK3QD clone 1 (+) group (6.0 ± 1.5% of grid boxes; p  
< 0.001), and the MOSERM ALK3QD clone 2 (+) group (11.6 ± 2.4% of grid boxes; p  <
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Figure 3.8 No effect of ALK3QD expression of mouse EOC cell line proliferation 
in vitro.
In order to assess cell proliferation, alamarBlue® assays were performed. 500 cells were 
seeded into 96 well plates for (A) MOSERM parental cells, MOSERM ALK3QD clone 1 
(+) and clone 2 (+), (B) MASC2 parental cells, MASC2 ALK3QD clone 1 (-) and clone 2 
(-), (C) 4306 parental cells, 4306 ALK3QD clone 1 (-) and clone 2 (+). Fluorescence 
units were then measured 12 hours after the initial seeding time in order to ensure equal 
seeding densities (day 0), and fluorescence units were then subsequently measured again 






Figure 3,9 ALK3QD expression in mouse EOC cell lines influences the 
angiogenic potential of cells on the chick CAM in vivo.
1 x 105 cells for each of the MOSERM, MASC2, and 4306 cell lines as well as for their 
respective ALK3QD clones were embedded in collagen. The collagen with mouse EOC 
cells was then inserted between 2 mesh grids, and placed on the surface of the chick 
CAM for 3 days, at which time angiogenesis was quantified. Angiogenesis was 
quantified by calculating the percentage of grid boxes within each mesh that were 
positive for blood vessel sprouting. Note that if a grid is determined to be positive for 
blood vessel sprouting, the grid count will only be given a score of one regardless of how 
many sprouts are within that grid box. The percentage of grids that are positive for blood 
vessel sprouting for (A) MOSERM, MOSERM ALK3QD clone 1 (+) and clone 2 (+),
(B) MASC2, MASC2 ALK3QD clone 1 (-) and 2 (-), (C) 4306, 4306 ALK3QD clone 1 
(-) and clone 2 (+) are shown. Error bars represent standard error of the mean for the 
average percentage of positive grids based on at least 7 mesh grids per group. Different 
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0.05). However, there are no statistically significant differences in angiogenic sprouting 
between the PBS, MOSERM ALK3QD clone 1 (+), or MOSERM ALK3QD clone 2 (+) 
treatment groups. Collagen onplants containing MASC2 parental cells contributed to new 
blood vessel sprouting on the chick CAM in 12.0 ± 2.7% of the grid boxes (Figure 3.9B). 
However, this degree of sprouting is not significantly different from the PBS group (9.5 ± 
0.7% grid boxes), MASC2 ALK3QD clone 1 (-) group (14.4 ± 0.7% grid boxes), or the 
MASC2 ALK3QD clone 2 (-) treatment group (15.4 ± 0.9% grid boxes). Conversely, the 
degree of angiogenic sprouting in the MASC2 ALK3QD clone 1 (-) and clone 2 (-) 
treatment groups is significantly greater than in the PBS control group (p < 0.05). Finally, 
13.6 ± 1.0% of grid boxes exhibited new blood vessel sprouting in collagen onplants 
containing 4306 parental cells (Figure 3.9C), which is significantly greater than blood 
vessel formation levels in the PBS control group (10.3 ± 0.7% grid boxes; p  < 0.05). 
Although there is a trend towards increased blood vessel sprouting in the 4306 ALK3QD 
clone 1 (-) group (16.8 ± 1.1% grid boxes), it is not significantly different from the 4306 
parental group. Conversely, 4306 ALK3QD clone 2 (+) collagen onplants exhibit new 
blood vessel sprouting in 9.7 ± 0.7 % o f grid boxes, which is significantly decreased 
compared to both the 4306 parental (p < 0.05) and 4306 ALK3QD clone 1 (-) groups (p < 
0.01) .
3.10 Treatment of mouse EOC cells with exogenous BMP4, Noggin, or BMP type
1 receptor inhibitor LDN-193189
In order to support my ALK3QD findings, we investigated whether short-term 
changes in BMP pathway signaling expression would have functional consequences on
cell proliferation and angiogenesis. Therefore, the three mouse EOC cell lines were 
treated with exogenous BMP4, Noggin (extracellular antagonist to inhibit BMP ligand 
binding) (Groppe, Greenwald et al. 2002) or LDN-193189 (BMP type 1 receptor 
inhibitor) (Yu, Deng et al. 2008). We first wanted to confirm that exogenous treatment 
with BMP4, Noggin, or LDN-193189 would affect the BMP signaling pathway, and to 
determine the duration of these effects. Therefore, cells were treated at the onset of the 
experiment, and protein was isolated from cells at multiple time points over three days 
(30 min, 4 hours, 24 hours, 48 hours, and 72 hours). Upon treatment with lOng/mL 
BMP4, protein levels of phospho-Smad 1/5/8 were increased in all three mouse EOC cell 
lines within 30 minutes (Figure 3.10A). The increase in phospho-Smadl/5/8 levels in 
MOSERM cells remained elevated up to the last time point at 72 hours, whereas the 
effect was diminished in MASC2 and 4306 cells by 24 hours. To a lesser extent, Idl 
protein expression was upregulated in MOSERM cells after 4 hours, and remained 
upregulated at 72 hours. Conversely, there were no consistent changes in Idl expression 
in the other cell lines.
After treatment with either 50ng/mL Noggin or 40nM LDN-193189, phospho- 
Smad 1/5/8 protein levels decreased in all three cell lines within 30 minutes (Figures 
3.10B and 3.10C). While these effects were sustained over the 72 hours of the experiment 
in MOSERM cells, phospho-Smad 1/5/8 expression began to noticeably increase back 
towards baseline levels after approximately 24-48 hours in the MASC2 and 4306 cells 
that were treated with Noggin and LDN-193189. Treatment with either of these BMP 
signaling inhibitors did not have an effect on Idl protein expression in MOSERM or
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Figure 3.10 Changes in BMP signaling as a result of treatment of mouse EOC cell 
lines with BMP4, Noggin, or LDN-193189.
Changes in downstream BMP signaling at multiple time points (30min, 4h, 24h, 48h, 
72h) after (A) lOng/mL BMP4 treatment, (B) 50ng/mL Noggin treatment, or (C) 40nM 
LDN-193189 treatment were assessed using anti-phospho-smad 1/5/8 and anti-IDl. 
Western blotting was performed using 50pg of total cellular protein, and equal loading 
was assessed with anti-Smadl and anti-actin. BMP signaling was considered to be 
upregulated or downregulated based on a change in phospho-Smad 1/5/8 protein 
expression. BMP4 treatment resulted in an upregulation of BMP signaling, while 
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MASC2 compared to untreated cells. Idl expression did decrease in 4306 cells by 30 
minutes, although it began to increase back to levels in untreated cells by 24 hours.
3.11 Changes in BMP signaling due to BMP4, Noggin, or LDN-193189 treatment 
do not affect cell proliferation or cell survival in vitro
In order to determine the functional consequences of the changes that were seen 
in protein expression levels in the BMP signaling pathway as a result of short-term 
BMP4, Noggin, or LDN-193189 treatment, cell proliferation and survival were initially 
assessed. For each cell line, BMP4 and Noggin treated cell proliferation was compared to 
parental cell line proliferation in growth media. Cell proliferation due to LDN-193189 
treatment was compared to cells that were grown in media with 3 DMSO: 1 chloroform, 
which is the solvent for LDN-193189. In vitro alamarBlue® assays were completed over a 
five day period, and fluorometric counts of wells were taken each day. For the 
MOSERM, MASC2, and 4306 cell lines, the average fluorometric counts for parental 
cells, BMP4 treatment, or Noggin treatment were not significantly different from one 
another at day 5 ( Figure 3.11). Similarly, there were no significant differences in the day 
5 fluorometric counts for any of the three cell lines between 3 DMSO: 1 chloroform and 
LDN-193189 treatments.
The ability of each of the three mouse EOC cell lines to survive in serum-free 
conditions in vitro after treatment was also evaluated. As with the in vitro cell 
proliferation assay, cell survival was assessed every 24 hours over 5 days by alamarBlue® 
fluorometric counts. However, cells were grown in serum-free media instead of media 
with 5% FBS. Similar to our findings with respect to cell proliferation, changes in the
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Figure 3.11 No effect of BMP4, Noggin, or LDN-193189 treatment of mouse EOC 
cell lines on cell proliferation in vitro.
In vitro alamarBlue® assays were performed to assess cell proliferation, which was 
compared between parental cells, BMP4-treated cells, Noggin-treated cells, LDN193189- 
treated cells, and cells treated with the solvent for LDN193189 (3 DMSO:l chloroform). 
500 cells in media with 5% FBS were seeded into 96 well plates for (A) MOSERM cells 
and respective treatments, (B) MASC2 cells and respective treatments, and (C) 4306 cells 
and respective treatments. Fluorescence units were then measured 12 hours after the 
initial seeding in order to ensure equal seeding densities (day 0), and fluorescence units 
were then subsequently measured again at multiple time points (day 1, day 2, day 3, day 












ability of cells to survive were not statistically significant among any of the three cell 
lines for any treatment (Figure 3.12). Interestingly, the fluorescence unit counts for the 
4306 cell line and its respective treatment groups plateau over the five day experimental 
period, whereas the fluorometric counts for the MOSERM and MASC2 cell lines steadily 
decrease between days 1 and 5.
3.12 Treatment of mouse EOC cell lines with exogenous BMP4 ligand decreases
the ability of cells to induce angiogenesis in vitro
Since short-term treatment with BMP4, Noggin, or LDN-193189 did not affect 
cell proliferation or survival, I sought to determine whether these treatments affected the 
ability of the mouse EOC cell lines to induce angiogenesis in vitro. This is because there 
was an inverse correlation between BMP signaling levels in ALK3QD clones and the 
angiogenic potential of these cells. Therefore, parental cells were treated overnight for 12 
hours with media containing lOng/mL BMP4 or 50ng/mL Noggin. After this period of 
time, treated cells were co-cultured with HUVECs in low serum-containing media (1% 
FBS) on a layer of Matrigel in the wells of 96-well plates. After 6 hours of incubation, 
multiple images were taken of each well at 100X magnification. Treatment with BMP4 
significantly decreased HUVEC branching from an average of 16.5 ± 0.5 branches per 
field of view for untreated MOSERM cells to 14.3 ± 0.5 branches per field of view in 
BMP4-treated MOSERM cells (Figure 3.13A; p  = 0.005). Similarly, HUVEC branching 
significantly decreased from 8.2 ± 0.9 to 5.4 ± 0.6 branches per field of view between 
untreated MASC2 cells and BMP4-treated cells (Figure 3.13B; p  = 0.04). As well, 
HUVEC branching significantly decreased from HUVECs co-cultured with untreated
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Figure 3.12 No effect of BMP4, Noggin, or LDN-193189 treatment of mouse EOC 
cell lines on cell survival in vitro.
In vitro alamarBlue® assays were performed to assess cell survival, which was compared 
between parental cells, BMP4-treated cells, Noggin-treated cells, LDN193189-treated 
cells, and cells treated with the solvent for LDN 193189 (3 DMSO:l chloroform). 5000 
MOSERM cells, 5000 MASC2 cells, or 10,000 4306 cells in serum-free media were 
seeded into 96 well plates for (A) MOSERM cells and respective treatments, (B) MASC2 
cells and respective treatments, and (C) 4306 cells and respective treatments. 
Fluorescence units were then measured 12 hours after the initial seeding in order to 
ensure equal seeding densities (day 0), and fluorescence units were then subsequently 
measured again at multiple time points (day 1, day 2, day 3, day 4, day 5). Each data 



































































Figure 3.13 Short-term treatment of mouse EOC cell lines with BMP4 or Noggin 
affects ability of cells to induce angiogenesis in vitro.
1 x 104 HUVECs were plated onto Matrigel and co-incubated with 5000 MOSERM cells, 
MASC2 cells, or 4306 cells in low serum-containing media (1% FBS) in 96 well plates. 
After 6 hours, angiogenesis was quantified by counting the number of branches formed 
by HUVECs per field of view in each well at 100X magnification. Branch counts for (A) 
MOSERM cells and respective treatments, (B) MASC2 cells and respective treatments, 
(C) 4306 cells and respective treatments are shown. Untreated cell branch counts per field 
of view are represented by black bars, while branch counts for BMP4 or Noggin-treated 
cells are represented by grey bars. Error bars represent standard error of the mean for the 
average number o f branches based on at least 4 wells per group. Asterisks indicate 
statistically significant differences within each pair of columns (p < 0.05). Pairwise 
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4306 cells at 10.7 ± 0.2 branches per field of view to 8.9 ± 0.7 branches per field of view 
in co-cultures with BMP4-treated 4306 cells (Figure 3.13C;p  -  0.04). Upon treatment of 
cells with Noggin for 12 hours, branching was increased relative to untreated cells by 1.2 
±1.1 branches per field of view for MOSERM Noggin-treated cells, 3.1 ± 1.0 branch 
points per field of view for MASC2 Noggin-treated cells, and by 2.3 ± 0.6 branch points 
per field of view for 4306 Noggin-treated cells. However, this trend towards increased 





Ovarian cancer continues to be a poorly understood disease with respect to the 
signs and symptoms relating to the early stages o f EOC, as well as with respect to the 
molecular mechanisms that contribute to its progression from a localized tumour that is 
confined to the ovaries to one that can metastasize to distant sites within the peritoneal 
cavity (Goff, Mandel et al. 2007). The poor understanding of this disease is highlighted 
by it having the highest mortality rate of any gynaecological cancer in the developed 
world, and decreases in this mortality rate have been relatively minimal when compared 
to other cancers that have seen more successful improvements in mortality rates over the 
past 15 years such as breast cancer (Canada 2010). Therefore, several key approaches 
must be employed in order to significantly reduce the high mortality rates that are 
associated with EOC in the future. One of these approaches is to improve current models 
of EOC in vitro and in vivo, or to develop novel model systems that can be efficiently 
used to study various aspects of EOC progression. Another key approach will be to 
further our understanding of the role(s) of molecular signaling pathways that have been 
implicated in other forms of cancer and specifically EOC, such as the BMP signaling 
pathway (Shepherd and Nachtigal 2003; Moll, Millet et al. 2006; Theriault, Shepherd et 
al. 2007; Shepherd, Theriault et al. 2008; Ma, Ma et al. 2010; Pils, Wittinger et al. 2010; 
Shepherd, Mujoomdar et al. 2010; McLean, Gong et al. 2011).
102
My studies have shown that the relative abilities of the MOSERM, MASC2, and 
4306 mouse EOC cell lines to form tumours on the chick CAM correlates with their 
differential abilities to enhance angiogenesis in vitro. Importantly, I was also able to 
detect these differences in angiogenic potential in vivo using the chick CAM collagen gel 
angiogenesis onplant assay. I have also shown that in addition to normal mouse OSE 
cells, the MOSERM, MASC2, and 4306 cell lines all express measurable, but distinct 
levels of BMP4 and its required intracellular signaling components. ALK3QD clones 
created from each cell line with increased BMP signaling relative to parental cells formed 
significantly smaller tumours on the chick CAM, while clones with decreased BMP 
signaling formed larger tumours on the chick CAM relative to parental cells. 
Additionally, increased BMP signaling in mouse EOC cell lines leads to decreased 
HUVEC branching in vitro, and decreased blood vessel formation in vivo using the chick 
CAM angiogenesis onplant assay. Conversely, cells with decreased BMP signaling 
exhibited increased levels of angiogenesis both in vitro and in vivo.
With respect to EOC mouse cells, there is only one mouse EOC cell line that has 
been well characterized in multiple studies, which is the ID8 mouse EOC cell line 
(Pengetnze, Steed et al. 2003). ID8 cells were created from normal mouse OSE cells that 
spontaneously transformed after repeated passaging in vitro. This cell line has multiple 
benefits because it exhibits an upregulation of Src tyrosine kinase, FAK, and PI3K/AKT 
signaling activation that in combination increase the rate of growth of ID8 cells, and 
decrease apoptosis. These signaling pathways have also been shown to be dysregulated in 
a large percentage of ovarian cancers (Judson, He et al. 1999; Wiener, Windham et al. 
2003; Huang, Zhang et al. 2011; Tanaka, Terai et al. 2011). Additionally, ID8 cells are
able to form tumours and ascites when injected into mice with intact immune systems 
(Roby, Taylor et al. 2000). However, other than this cell line, there are only a couple 
other mouse EOC cell lines that have been used and partially characterized in the 
literature (Szotek, Pieretti-Vanmarcke et al. 2006; Goodell, Belisle et al. 2009), although 
to a lesser extent than ID8 cells. Therefore, the development and characterization of other 
mouse EOC cell lines will be very beneficial and will contribute to an improved 
understanding of EOC and its progression. As a result, our lab obtained three mouse 
ovarian cancer cell lines that I partially characterized both in vitro and in vivo. The first 
cell line is the 4306 cell line that overexpresses mutant Kras ' 120 in addition to having an 
inactivated Pten tumour suppressor gene (Dinulescu, Ince et al. 2005). Secondly, the 
MOSERM line ectopically expresses the Ras and Myc oncogenes in addition to a 
temperature sensitive mutant of SV40 large T antigen (Yao, Li et al. 2006). Thirdly, the 
MASC2 cell line expresses SV40 large T antigen (Laviolette, Garson et al. 2010). 
Although the 4306 cell line has been shown to possess an intact Mullerian Inhibiting 
Substance (MIS) signal transduction pathway (Szotek, Pieretti-Vanmarcke et al. 2006), 
these three mouse EOC cell lines have otherwise been poorly characterized in the 
literature. Therefore, our characterization of the MOSERM, MASC2, and 4306 cell lines 
with respect to their in vivo tumour formation abilities on the chick CAM, in vitro 
proliferation, in vitro angiogenesis, and angiogenesis on the chick CAM will support the 
use o f these cell lines as additional tools to gain a better understanding of EOC.
Also contributing to our lack of understanding of EOC is a limited number of 
effective in vivo animal model systems that can recapitulate multiple aspects of EOC 
tumour progression (Pengetnze, Steed et al. 2003). The chick CAM is a useful animal
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model system that has been used to study many types of cancer including colon (Kim,
Hur et al. 2011), melanoma (Liang, Butterfield et al. 2011), neuroblastoma (Azar, Azar et 
al. 2011), oral squamous cell carcinoma (Hseu, Wu et al. 2011), pancreatic cancer 
(Laklai, Laval et al. 2009). In addition, this system can been used to investigate several 
aspects of tumourigenesis such as primary tumour growth (Gao, Cao et al. 2004; Liang, 
Butterfield et al. 2011), metastasis (Subauste, Kupriyanova et al. 2009), and angiogenesis 
(Azar, Azar et al. 2011; Chim, Qin et al. 2011; Liang, Butterfield et al. 2011). With 
respect to ovarian cancer, the chick CAM can be used to simulate the physiological 
microenvironment that metastatic EOC cells would be subjected to in the peritoneal 
cavity when encountering mesothelial surfaces of abdominal organs and a vascularized 
substratum upon which cells will form secondary metastases (Schmitt and Matei 2011).
The chick CAM has previously been applied to EOC to study the effects of two 
naturally occurring flavonoids, Kaempferol and Apigenin, on tumour growth and 
angiogenesis. Both of these flavonoids were shown to decrease angiogenesis in chick 
CAM assays with human ovarian cancer OVCAR3 cells, while Kaempferol was also 
shown to limit OVCAR3 tumour growth on the chick CAM (Fang, Zhou et al. 2007; Luo, 
Rankin et al. 2009). Additionally, malignant ascites fluid (MAF) has been shown to 
decrease surface capillary formation when it was applied directly to the surface of the 
chick CAM (Richardson, Gunawan et al. 2002). We have added evidence in addition to 
these studies that further supports the use of the chick CAM as an effective model system 
that can be used study tumour formation and angiogenesis in EOC progression. 
Importantly, other than our collaborations with Dr. John Lewis and his lab, only a few 
other labs in the world have used the collagen onplant assay on the chick CAM to
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quantify angiogenesis (Nguyen, Shing et al. 1994; Seandel, Noack-Kunnmann et al.
2001; Zijlstra, Seandel et al. 2006). Although other chick CAM angiogenesis assays can 
be useful, they are only qualitative and it can be difficult to distinguish new blood vessel 
formation from preexisting blood vessels (Staton, Reed et al. 2009). Therefore, our lab is 
using the novel chick CAM onplant assay that has the ability to detect more subtle 
changes in angiogenesis by quantifying new blood vessel formation, which may not have 
been detectable in our studies if traditional chick CAM angiogenesis assays that are more 
qualitative had been used (Nguyen, Shing et al. 1994).
Angiogenesis is one the essential hallmarks of cancer because tumours require 
access to a blood supply in order to receive oxygen and nutrients, and to be able to 
excrete waste products such as carbon dioxide (Hanahan and Folkman 1996). In fact, 
without the ability to induce a certain level of angiogenesis, tumours cannot grow and 
survive beyond a size of 1-2 mm in diameter (Bergers and Benjamin 2003). The 
importance of angiogenesis in the progression o f cancer is reflected by the large number 
of current trials involving anti-angiogenic compounds that are being tested in patients 
with metastatic ovarian cancer. For example, there are over 25 ongoing phase I, phase II, 
or phase III clinical trials that involve one or more of the anti-angiogenic agents 
Bevacizumab, Dasatinib, Imatinib, or Sorafenib as monotherapies or in combination with 
other drugs (Schmitt and Matei 2011). Due to the importance of angiogenesis in cancer 
metastasis, it is essential to gain a thorough understanding of the signaling pathways that 
play an important role in this process. Therefore, I have focused my studies on the role of 
the BMP signaling pathway on tumour angiogenesis. BMP signaling has been shown to 
have an important pro-angiogenic role in many cancers such as hepatocellular cancer
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(Maegdefrau, Amann et al. 2009) and melanoma (Rothhammer, Bataille et al. 2007), but 
has also been implicated in having an anti-angiogenic role in others such as lung cancer 
(Buckley, Shi et al. 2004). However, the role o f BMP signaling in the process of 
angiogenesis has never been previously studied in EOC. Based on my findings, I propose 
that one of the important mechanism(s) by which increased BMP signaling is able to limit 
the ability of mouse EOC cells to form tumours on the CAM is by decreasing the 
angiogenic potential of these cells. Interestingly, my characterization of TGFp/BMP gene 
expression in the three mouse EOC cell lines also supports these findings. For example, 
MASC2 cells exhibit significantly higher expression levels of BMP4, as well as Idl and 
ld2. These cells are also unable to form visible tumours on the chick CAM, and do not 
significantly induce angiogenesis relative to growth media and PBS controls for in -vitro 
and in vivo angiogenesis assays, respectively. This is compared to MOSERM and 4306 
cells that exhibit lower expression levels of BMP signaling genes, are able to form 
tumours on the chick CAM, and significantly enhance angiogenesis relative to controls 
both in vitro and in vivo. Therefore, I propose that MASC2 cells are unable to form 
tumours on the chick CAM due to the fact that they have a limited ability relative to other 
mouse EOC cell lines to enhance angiogenesis, and this decreased ability to enhance 
angiogenesis is partially due to increased BMP signaling.
Although angiogenesis is essential for tumours to metastasize, there are other 
mechanisms that are also important in cancer progression. Several of these mechanisms 
have been studied with respect to the BMP4 signaling pathway and its role in EOC 
progression in several studies. For example, increased BMP4 signaling in vitro has been 
shown to lead to morphological changes in cells that are characteristic of an EMT
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transition (Shepherd and Nachtigal 2003; Theriault, Shepherd et al. 2007), a loss of cell 
adhesion (Shepherd, Mujoomdar et al. 2010), increased motility, and increased invasive 
potential (Theriault, Shepherd et al. 2007). Similarly, studies that involve decreasing the 
activity level of the BMP signaling pathway through the use of Noggin and Chordin in 
EOC cells decreased their migration and invasive potential, as well as increased cell 
adhesion (Moll, Millet et al. 2006; Theriault, Shepherd et al. 2007). However, a recent 
conflicting study involving constitutively active BMP signaling with ALK3QD has 
correlated increased BMP signaling with a decreased ability of EOC cells to form 
intraperitoneal tumour implantations in addition to decreased ascites formation when 
injected into mice (Shepherd, Mujoomdar et al. 2010). My findings show that mouse 
EOC cells with increased levels of BMP signaling form significantly smaller tumours on 
the chick CAM, which acts to simulate the physiological microenvironment that EOC 
cells would encounter when metastasizing to the substratum of the peritoneal cavity , and 
this decreased ability to form secondary tumours is due to a decreased ability to enhance 
angiogenesis. Therefore, my data supports the previously conflicting study that implicates 
BMP signaling as an anti-tumourigenic pathway in the later stages of EOC progression.
In order to connect these two disparate groups of data, I propose that BMP signaling has 
unique roles at different stages of ovarian cancer progression. During the early stages of 
EOC tumour progression, upregulated BMP signaling is advantageous so that EOC cells 
can lose their adhesion capabilities, and as a result are able to shed from the primary 
tumour into the peritoneal cavity. However, in later stages of ovarian cancer progression, 
downregulated BMP signaling is required to promote spheroid formation and the 
establishment of secondary métastasés at distant sites within the peritoneal cavity. The
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ability to recruit vasculature is a key component for tumours to be able to establish these 
secondary métastasés. Decreased BMP signaling will therefore improve the ability of 
tumours to recruit vasculature at these secondary sites, and as a result will be better able 
to grow and survive upon reattachment.
Due to the complicated nature of the BMP signaling pathway both with respect to 
its activation and regulation, as well as its multiple roles in various stages of EOC 
progression, further research will be required in order to gain a more thorough 
understanding of this pathway in ovarian cancer despite the recent and ongoing 
advancements in our lab. However, this pathway has important potential future 
implications for prognostics. For example, elevated BMP4 and potentially BMP2 levels 
with ovarian cancer could be considered in order to assist with prognoses for patients. 
This is because decreased BMP levels in patients would be considered to be a negative 
prognostic factor due to the fact it would correlate with an increased ability of the EOC 
tumour to further metastasize, and as a result correlate with lower survival outcomes. 
Additionally, targeting the BMP pathway has potential therapeutic value. For example, in 
patients with more advanced stages of EOC in which the tumour has already begun to 
metastasize, therapeutics could possibly be used to increase levels of BMP signaling in 
EOC cells. This could decrease the ability of additional EOC cells from forming 
secondary nodules, and could also decrease the survival ability of already metastasized 
tumours by limiting their abilities to recruit a sufficient blood supply.
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4.2 Future directions
BMP signaling as an anti-angiogenic pathway in cancer is a fairly novel concept 
that has only come to light in the past decade (Buckley, Shi et al. 2004; Stabile, Mitola et 
al. 2007). Of these studies, there is only one of which we are aware that suggests a 
potential downstream target of increased BMP signaling that contributes to decreased 
angiogenesis in cancer. This study by Stabile et al. suggests that in lung cancer, increased 
BMP4 signaling leads to decreased VEGF protein expression (Stabile, Mitola et al.
2007). Our lab plans to contribute to BMP signaling research in cancer by investigating 
potential downstream targets of increased BMP signaling that lead to a decreased ability 
of mouse ovarian cancer cells to enhance angiogenesis. This will be accomplished by 
comparing the mRNA or protein expression levels of well known pro-angiogenic factors 
such as VEGF as well as angiogenesis inhibitors such as TSP-1 in our ALK3QD- 
transfected clones, BMP4-treated cells, Noggin-treated cells, or LDN-193189-treated 
cells. Expression levels will then be compared to the untreated parental mouse EOC cell 
lines. An alternative approach will be to use RNA or protein-based array screens that are 
specifically designed to evaluate a large number of angiogenic growth factors and related 
proteins. We also plan to conduct future experiments in order to provide additional 
evidence that angiogenesis is responsible for the differential abilities of the three mouse 
EOC cell lines to form tumours on the chick CAM. Based on my current data, I 
hypothesize that MASC2 cells would be able to form tumours on the chick CAM if the 
angiogenic potential of these cells was significantly increased. Therefore, MASC2 cells 
will be transfected in order to overexpress a major pro-angiogenic factor such as VEGF,
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after which time these transfected cells will be inoculated onto the surface of the chick 
CAM to assess tumour growth.
My studies have further supported the use of the chick CAM as an effective 
model system that can be used to study EOC. Although there has been one study that has 
investigated the effects of whole MAF from patients with ovarian cancer on angiogenesis 
by inoculating this fluid onto the surface of the CAM (Richardson, Gunawan et al. 2002), 
there have been no studies of which we are aware that have used the chick CAM to study 
primary human EOC cells specifically. Therefore, my findings relating to the role of 
BMP signaling in mouse EOC cells on the chick CAM now provides an initial starting 
point from which our lab will be able to assess the effect of altered BMP signaling on 
tumour growth and angiogenesis in primary human EOC cells using this model system. 
These primary human EOC cells will be directly isolated from patient ascites fluid by 
using a protocol that was previously developed by Dr. Trevor Shepherd (Shepherd, 
Theriault et al. 2006). Additionally, the ease of use and large-scale applicability of the 
chick CAM model system provides unique opportunities in the future to rapidly test 
novel therapeutic compounds, specifically compounds targeting BMP signaling pathway 
in EOC that can be directly tested in this model system. For example, anti-angiogenic 
agents that would act by enhancing BMP signaling and therefore decrease the angiogenic 
potential of metastatic EOC tumours could be applied to the chick CAM, which could 
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